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ABSTRACT
This dissertation builds three prediction tools to dynamically predict the onset of
acute graft-versus-host disease (aGVHD) with longitudinal biomarkers. Acute graft-
versus-host disease is a complication for patients who have received allogeneic bone
marrow transplant, and it is fatal for some patients. Clinicians could benefit from
these prediction tools to identify patients who are at risk and who are not, and thus
assign appropriate interventions.
Our first project introduces how to apply joint modeling with latent classes (JMLC)
and landmark analysis to aGVHD data. In JMLC, we group all aGVHD-free patients
into one latent class and define that class as the “cure” class. In landmark analysis,
we incorporate patients’ biomarker information up to the landmark time to gain more
efficiency. Computer simulations show that both methods adjust for the measurement
error, and that JMLC outperforms landmark analysis when the functional form of
the biomarker profile is correctly specified.
In our second project, we describe how to execute dynamic prediction with the
pattern mixture model, in which each patient is classified by his/her time-to-aGVHD,
and patients in the same group share the same mean profile of biomarkers. The pat-
tern mixture model is easy to execute and straightforward to interpret. Simulations
indicate that the pattern mixture model controls loss of accuracy in predictions.
In our third project, we incorporate censored cases to generalize the pattern mix-
xii
ture model in the second project. The simulation results demonstrate that this gen-
eralized pattern mixture model accurately estimates of the marginal pattern proba-
bilities, and thus better estimates early predictions compared to early predictions not
incorporating censored observations.
In our fourth project, we explain the process of parametric bootstrap in selecting
the number of latent classes in JMLC. Compared with the standard information-
based criteria in model selection in JMLC, our parametric bootstrap likelihood ratio
test (LRT) controls the Type I error well while maintaining sufficient power. We also
propose two sequential early stopping rules to relieve the computational burden of
bootstrap.
xiii
CHAPTER I
Introduction
1.1 Acute Graft-versus-Host Disease
Approximately every three minutes one person is diagnosed with a hematologic
cancer (blood cancer) in the United States (US), and approximately 160 people each
day die from a hematologic cancer in the US (the Leukemia and Lymphoma Soci-
ety, 2016). Based on Cancer Facts & Figures (2016) released by National Cancer
Institute, over 60,000 Americans are expected to be diagnosed with leukemia, one of
major hematologic cancers together with lymphomas and myeloma. There are mul-
tiple treatment strategies for hematologic cancer, such as chemotherapy, radiation
therapy, immunotherapy, and hematologic stem-cell transplantation (HSCT). Among
them, HSCT is a rapidly evolving technique that offers a potential cure to hema-
tologic cancers and other hematologic disorders, such as primary immunodeficiency,
aplastic anemia, and myelodysplasia.
There are two main types of HSCT, autologous HSCT and allogeneic HSCT. Many
factors contribute to the choice of the two types of HSCT, including the type of can-
cer, the stage of cancer, the age of a patient, and the accessibility of matched donors
(Champlin, 2003). In autologous HSCT, a patient’s own stem cells are collected and
frozen prior to the high-dose chemotherapy, and then are reinfused. There are rarely
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graft failures and virtually no risk of graft-versus-host disease (GVHD), which is an
inflammatory disease caused by immune cells in the donor’s organ viewing the recip-
ients’ tissues as foreign and attacking them. Thus, the treatment-related mortality
rates of autologous HSCT patients are low. However, these patients are at increased
risk of relapse because there is a possibility that the graft is contaminated with tumor
cells.
Patients undergoing allogeneic HSCT receive stem cells from human leukocyte
antigen (HLA)-matched donors, who can be either siblings or unrelated donors. HLA
is a cell-surface protein that regulates the human immune system. The primary ben-
efit of allogeneic HSCT is that the graft is presumed to be tumor-free and there is
no prior marrow injury from chemotherapy. Moreover, there is an additional graft-
versus-tumor effect contributing to a lower recurrence rate. Hosing et al. (2003) found
that the probability of non-Hodgkin lymphoma (NHL) recurrence is 19% among al-
logeneic HSCT patients, compared with 74% in autologous HSCT patients (p-value
= 0.003). However, the overall survival after HSCT is not satisfactory (Center for
International Blood & Marrow Transplant Research, 2015). For example, as shown
in Figure 1.1, the three-year overall survival of patients after allogeneic HSCT with
early-stage acute myelogenous leukemia (AML) is around 60%, while for advanced-
stage patients it is only about 30%.
The main causes of mortality after allogeneic HSCT are relapse of cancer, GVHD,
infections and other complications, as shown in Figure 1.2. GVHD is one of the
major causes of non-relapse mortality (NRM), associated with approximately 20% of
deaths for both HLA matched sibling transplants and unrelated donor transplants in
2012-2013 in AML patients (Center for International Blood & Marrow Transplant Re-
search, 2015). The risk of GVHD increases with age; thus, allogeneic HSCT is usually
2
Figure 1.1: Survival of AML patients in early, intermediate and advanced stage of
cancer from 2003-2013 after allogeneic HSCT, with unrelated donor (left)
and HLA matched sibling donor(right)
restricted to younger patients in good physical condition. GVHD observed within 100
days after HSCT is named acute graft-versus-host disease (aGVHD), which occurs
in approximately half of allogeneic HSCT recipients (Ferrara et al., 2009; Weisdorf
et al., 2012). AGVHD occurs in the skin, liver, eyes, or gastrointestinal tract once
the donor’s cells have engrafted in the transplant recipient (Jacobsohn and Vogelsang,
2007). One reason for the high mortality rate associated with aGVHD is that it is dif-
ficult to diagnose early and accurately. AGVHD is a clinical diagnosis, mainly based
on observed certain symptoms such as fever, skin rash and/or increased dryness, and
can be supported with the help of histological confirmation from a biopsy.
At the time of diagnosis, aGVHD is graded by the number and extent of organ
involvement. There are two major systems used for grading aGVHD. The first sys-
tem is the International Bone Marrow Transplant Registry (IBMTR) grading system,
which grades severity of aGVHD using the letters A, B, C, and D, with A being least
severe and D being most severe. Grading is based upon visual symptoms associated
with aGVHD, including rash, diarrhea, and pain. The second system is the Glucks-
berg grading system, which grades severity of aGVHD using the Roman numerals
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Figure 1.2: Causes of Mortality of AML patients in early, intermediate and advanced
stage of cancer from 2003-2013 after allogeneic HSCT, with unrelated
donor (left) and HLA-matched sibling donor(right)
I, II, III, and IV, with I indicating least severe and IV indicating most severe. Like
IBMTR, Glucksberg includes physical symptoms in its grading. However, Glucksberg
also combines a patient’s daily living quality of life measured by their Eastern Co-
operative Oncology Group (ECOG) score. Treatment is assigned to patients based
on their grade of aGVHD severity. Currently steroids remain to be the standard
first-line treatment, which can reduce body’s immune response and reduce the num-
ber of T cells. However, less than 50% of patients will have a complete response to
steroids, and steroids have toxic side effects, including osteopenia and immunosup-
pression (Garnett et al., 2013).
Diagnosis of aGVHD based on clinical symptoms may be inaccurate because some
of the symptoms are not specific to aGVHD. Moreover, both clinicians and patients
want to avoid invasive biopsy confirmation. Thus, accurate diagnosis and prediction
of aGVHD through non-invasive measures are of great importance, because clinicians
want to avoid over-treatment and improve patients’ quality of life.
4
1.2 Biomarkers of aGVHD
Much research has been done to explore how biomarkers are related to aGVHD
and how they might be used in predicting the onset of aGVHD, NRM, and overall
survival (OS) (Paczesny et al., 2009). Candidate biomarkers for the prognosis of
aGVHD derive from three general categories: markers of generalized inflammation
(e.g., interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α)), lymphocyte surface
molecules (e.g., CD30), and end products secreted from damaged organs (e.g., Elafin
and Regenerating islet-derived 3 - α (REG3α)) (Chen and Cutler, 2013). Biomarker
levels in plasma often rise several weeks before the clinical disease becomes apparent,
making early prediction of the onset of aGVHD plausible (Levine et al., 2006).
Early research includes multiple small studies designed to identify individual blood
proteins as biomarkers of aGVHD. Symington et al. (1990) measured the concentra-
tion of serum TNF-α in 44 patients who had received HSCT and analyzed the corre-
lation between this concentration and the onset of aGVHD and its severity. The con-
centration of TNF-α was measured by enzyme-linked immunosorbent assay (ELISA)
and dichotimized into two categories: TNF-positive and TNF-negative. Via Fisher’s
Exact Test, researchers found a weak association between positive levels of TNF-α
and aGVHD onset (P = 0.06). Behar et al. (1996) explored whether one poorly
defined minor histocompatibility antigen, cluster of differentiation 31 (CD31) adhe-
sion molecule, could explain the high incidence rate of aGVHD among HLA-matched
patients. With 46 pairs of recipients of HSCT and their HLA-identical siblings, re-
searchers found that CD31 was a minor alloantigen, and non-identical genotypes of
CD31 between donor and recipient was associated with a high risk of aGVHD (P
= 0.004). These studies have revealed the value of biomarkers in the prediction of
aGVHD, even in small samples of patients. However, in the study by Symington et al.
(1990), patients’ serum samples were taken between 4 and 52 days post-transplant,
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and at the time of serum collection, some of the patients had had developed aGVHD.
Biomarkers collected at different times impairs the reliability of this study.
Some researchers suspected that the onset of aGVHD should reflect not only the
concentration of biomarkers, but also the change of biomarkers over time. Uguccioni
et al. (1993) made serial measurements of serum IL-8 concentration on 8 patients
with successful engraftment and 5 patients with aGVHD after HSCT. The IL-8 con-
centration was measured 20 days before the HSCT, and sequentially after HSCT.
Researchers found that the concentration of IL-8 decreased significantly among pa-
tients with successful engraftment. However, this IL-8 concentration did not change
significantly before and after HSCT among patients developing aGVHD. Another
study in 2006 identified that an increase in tumor necrosis factor receptor 1 (TNFR1)
on day 7 following allogeneic HSCT compared with its baseline value was strongly
correlated with aGVHD onset, NRM and OS (Levine et al., 2006). Both of the
two studies were case-control analyses, in which patients were classified as aGVHD
patients or aGVHD-free survivors. They used repeatedly collected biomarkers to im-
prove efficiency, however, they lost information by ignoring the true times-to-aGVHD.
Some researchers also argued that differences of any single protein did not have
enough specificity and sensitivity to be of clinical use (Paczesny et al., 2009). Thus,
researchers have incorporated multiple biomarkers in a multivariate logistic regression
model that could hopefully better confirm the diagnosis of aGVHD in patients with
onset of clinical symptoms of aGVHD, and provide prognostic information indepen-
dent of aGVHD severity evaluated based on clinical symptoms (Paczesny et al., 2007,
2009). Harris et al. (2013) found that combining a panel of four biomarkers (IL-2Rα,
TNFR1, elafin and REG3α) at day 7 post-HCT and five pre-HCT clinical risk factors
produced good prediction of grade II-IV aGVHD following related donor HSCT. This
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combination of biomarkers obtained a 77% sensitivity, and clinical factors proved to
be significantly more predictive of aGVHD than a model with clinical risk factors
only (P < 0.001).
Due to the convenience of obtaining biomarkers from plasma, researchers discov-
ered that the prediction of aGVHD onset could be calibrated by a sequential pre-
diction process. Two separate multivariate logistic models were built with IL-2Rα,
TNFR1, and elafin at day +7 and day +14, and a new prediction rule was designed
using the prediction probabilities of the two models. Patients were labeled as high
risk if the predicted probability of aGVHD with day +7 biomarkers was above 0.64.
Among the rest low risk group, patients were re-classified as high risk if the predicted
probability of aGVHD with day +14 biomarkers was above 0.41 (Paczesny et al.,
2011). This approach could be viewed as the first attempt of dynamic prediction of
aGVHD.
Moreover, researchers discovered that the severity of symptoms at the onset of
aGVHD did not accurately define risk of death, and that most patients were treated
similarly with high dose systemic steroids (Levine et al., 2014, 2015). Thus, Harris
et al. (2013) built a prognostic score for aGVHD based on TNFR1, REG3α, IL2Rα,
elafin and suppressor of tumorigenicity 2(ST2). This new aGVHD grading system
based solely on biomarkers reclassified a significant number of patients (n = 21/79,
27%) and produced more accurate risk groups than Glucksberg grades, the most pop-
ular grading system of aGVHD based on clinical symptoms, resulting in better NRM
prediction as well (Harris et al., 2013; Vander Lugt et al., 2013).
The aforementioned research has proved the efficacy of biomarkers in the predic-
tion and prognosis of aGVHD. Moreover, the sequential prediction model invokes the
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need of utilizing repeatedly collected biomarkers to make more accurate prediction
of aGVHD. The fundamental theory behind this idea is that though the most recent
biomarker values are more related to aGVHD onset than earlier measures, the entire
biomarker history offers more information than a single observation. The inexpen-
sive and highly effective ELISA enables biomarkers to be regularly collected. In this
project, we will explore various of methods predicting the onset of aGVHD with re-
peated biomarkers. By doing this, we could achieve aGVHD prediction as early as
possible, and refine this prediction whenever a new biomarker observation is available.
1.3 aGVHD Biomarker Dataset
In line with the previous statement, this research is structured for a study con-
ducted by University of Michigan Blood and Marrow Transplant Program. This
study includes 381 patients who underwent allogeneic HSCT between the year 2000
and 2010 (Vander Lugt et al., 2013). Their plasma samples were collected weekly
throughout the first month, and then monthly thereafter until the first of aGVHD
onset or day 100 after HSCT. The concentrations of multiple plasma biomarkers,
such as suppression of tumorigenicity 2 (ST2), elafin and IL-2Rα, were measured and
recorded. The published data only contain biomarker measurements at day 0, day
14 and day 28 after HSCT, with around 30% missing values at day 14 and day 28.
Figure 1.3 shows the concentration of one of the recorded biomarkers, IL2-rα.
In this dataset, patients had at most three repeated biomarker measures, which
were insufficient to support a sophisticated model with several parameters. So we
simulate data according to this real dataset and evaluate the performance of our
methods on the simulated data.
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Figure 1.3: IL2-rα levels at day 7, 14, and 28 post HSCT among 381 patients in the
University of Michigan Bone Marrow Transplantation program
There are several main features of the simulated data. First, the patients are of
various risks of aGVHD, and each aGVHD risk group has a different biomarker trajec-
tory. AGVHD is conventionally defined to occur within 100 days of HSCT, and there
are a proportion of patients who will never develop aGVHD within the period of data
collection. Moreover, according to the document shared by Center for International
Blood & Marrow Transplant Research (2005), there are four identifiable patterns of
the frequency trajectory of anti-host T cells, as demonstrated by Figure 1.4. There-
fore, we assume patients are from four aGVHD risk groups: high-, medium-, low-risk,
and aGVHD-free, with aGVHD risk level-specific mean biomarker profiles. Second,
serum biomarker collection tends to be regular and systematic, occurring at specific
time intervals after HSCT. Thus, there is little occurrence of missing biomarker val-
ues. Third, there is no missingness in time-to-aGVHD for all patients not in the
aGVHD-free group. The times-to-aGVHD are observed and recorded for all patients
except the aGVHD-free patients.
9
Figure 1.4: the clonal frequency of anti-host T cells over post-transplant period
1.4 Methods for Modeling Longitudinal Processes and Time-
to-Event
Modeling a longitudinal process of biomarker observations and a time-to-aGVHD
process individually will result in biased estimation of the mean trajectory of biomark-
ers over time and the hazard ratio quantifying the association between biomarkers and
the time-to-aGVHD. This bias is due to the mutual dependence between longitudinal
biomarkers and time-to-aGVHD. The time-to-aGVHD depends on the whole history
of biomarker levels, while the follow-up of biomarker values is truncated by the time-
to-aGVHD (Tsiatis and Davidian, 2004). We now review three existing methods for
analyzing times-to-event with repeated biomarkers.
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We define Y i = (Yi(t1), Yi(t2), · · · , Yi(tni)) as the biomarker history of subject i
at time (t1, t2, · · · , tni), where ni is the total number of biomarker observations for
subject i, for i = 1, 2, · · · , n. Let Ti denote the observed time for subject i, which is
the minimum of the time-to-event for subject i, T ∗i , and last follow up time Si. We
also define δi as the indicator of whether subject i experiences aGVHD (δi = 1) or is
censored (δi = 0). This notation is used throughout this chapter.
1.4.1 Time-varying Covariates in Times-to-Event
In a survival model with time-varying covariates, the record of subject i is sepa-
rated into several non-overlapping time intervals (t1, t2), (t2, t3), · · · , (tni−1, tni). Within
each time interval (tj−1, tj), the time-varying covariates hold constant values as Yj−1,
for j = 2, 3, · · · , ni. Each interval is coded as one record, thus one subject could have
multiple separate records. Standard approaches, i.e., Cox regression, can be applied
to this new long-format dataset. At each event time, the risk set is updated, and so
are the covariate values.
The key idea behind Cox regression with time-varying covariates is simple: co-
variates’ values are viewed as constant within intervals (Therneau and Lumley, 2011).
There are some main drawbacks of using time-varying covariates in the analysis of
times-to-event. First, there is no effort to separate the measurement error from true
values of time-varying covariates. Second, because biomarkers are only collected in-
termittently, the exact biomarker value at each event time may not be available.
When maximizing the partial likelihood of Cox model with time-varying covariates,
the last biomarker observation is carried forward (LOCF). This may lead to biased
inference of the association between biomarkers and time-to-event, especially when
we have serial multiple biomarkers up to a certain time point, which is shorter than
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the total length of follow-up (Fang et al., 2016). Moreover, Cox regression with time-
varying covariates is not designed for prediction, because one cannot know how the
time-varying covariates change over time. Thus, this approach is not useful in our
setting.
1.4.2 Joint Modeling
One popular approach to handle mutually dependent data is joint modeling (Song
et al., 2002; Yu et al., 2004; Proust-Lima et al., 2014). Since there is no easy closed-
form for the joint distribution of longitudinal biomarkers Yi and time-to-event (Ti, δi),
shared terms are brought in to introduce conditional independence between longitudi-
nal process and time-to-event. Two common approaches for expressing shared terms
are the latent classes (LC) or shared random effects (SRE), and the joint model is
named joint modeling with latent classes (JMLC) and joint modeling with shared
random effects (JMSR) correspondingly.
The JMLC and JMSR have fundamentally different assumptions in population
heterogeneity of biomarkers and time-to-event distributions. JMSR assumes the pop-
ulation all share the same profile of biomarkers, with the time-to-event depending
on individual-level deviations of biomarkers from the population mean. In contrast,
JMLC treats subjects as being from different risk groups, and the survival probability
only depends on the risk group membership (Blanche et al., 2015; Rizopoulos et al.,
2017). In practice, neither assumption fits better in all settings, and the choice be-
tween JMLC and JMSR should be made on a case-by-case basis. One major drawback
of joint modeling in general is the difficulty in model fitting. Because the LC and SRE
are unobservable, they need to be either integrated out of the model, or estimated
using either the Expectation-Maximization (EM) algorithm or Markov Chain Monte
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Carlo (MCMC).
1.4.3 Landmark Analysis
Another approach, landmark analysis, shows certain benefits over joint modeling
with respect to model fitting and interpretation. Zheng and Heagerty (2005) em-
ployed landmark analysis for dynamic prediction and defined it as partly conditional
modeling. van Houwelingen and Putter (2011) described how to apply landmark
analysis to settings with repeated biomarker observations and one final time-to-event
endpoint. A standard landmark analysis fits one separate survival model at each pre-
defined landmark time point, so it is easy to execute and straightforward to interpret
the parameters.
The main feature of landmark analysis is that at each landmark time, all the future
biomarker observations are ignored, and all subjects who have already experienced
the event are removed from the risk set. Although landmark analysis is straightfor-
ward and easy to execute, it is criticized by its coarse use of biomarker values (van
Houwelingen, 2007; van Houwelingen and Putter, 2011). First, the landmark analysis
abandons the whole biomarker history before the landmark time and only uses the
biomarker observations at the landmark time. When a biomarker value is missing,
the last observed biomarker value is carried forward to the landmark time. Second,
a landmark analysis ignores the measurement error of biomarker values and fits the
time-to-event model without adjusting for this noise. If the longitudinal biomarkers
are measured sparsely and irregularly, and also with measurement errors, landmark
analysis might not be an ideal approach.
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1.5 Structure of Dissertation
In the second chapter, we analyze longitudinal biomarkers and time-to-aGVHD
with both JMLC and landmark analysis. Both methods are modified specifically to
our setting. We introduce how to do model fitting and prediction with these two
methods, and compare their prediction performance. Though these two approaches
are well-accepted, both JMLC and landmark analysis have complex model specifica-
tion and the model fitting is time consuming. Thus, in the third chapter, we build a
pattern mixture model to predict the onset of aGVHD given longitudinal biomarker
values. This pattern mixture model is easy to execute and interpret. In the fourth
chapter, we generalized this pattern mixture model to incorporate censored cases.
The JMLC model used in the second chapter requires a pre-specified number of la-
tent classes, thus, in the fifth chapter, we propose a hypothesis testing based model
selection process to select the number of latent classes in JMLC. The future research
areas that can be explored further based on our current work are discussed after.
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CHAPTER II
Dynamic Prediction of Time-to-acute
Graft-versus-Host-Disease with Joint Modeling
and Landmark Analysis
2.1 Introduction
In this chapter, we use two methods to assess future risk of aGVHD based on
repeated biomarker observations. Our first approach uses a revised JMLC, which in-
cludes one latent class for those who will never develop aGVHD (aGVHD-free), and
several other classes defined by the risk of aGVHD. Given that one patient’s time-
to-aGVHD is beyond day 100, his/her aGVHD-free class membership is labeled at
the beginning in order to increase model identifiability. Our second approach applies
a landmark analysis that is modified to allow for patients from various aGVHD risk
groups.
These two methods both require a pre-specified number of risk classes among the
patients. This number can be a subjective choice made based on data visualization or
the clinicians’ prior medical knowledge of aGVHD. Moreover, previous studies have
also discussed choosing the number of latent classes based on the model selection re-
sults. For example, in a study of using prostate-specific antigen (PSA) to predict the
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risk of prostate cancer, a separate model was fitted for each of a varying number of
latent classes; the model with the least value of Bayesian information criterion (BIC)
was chosen as the final model (Lin et al., 2002).
For the purposes of this project, we will fix the number of latent classes ac-
cording to the medical characteristics of aGVHD patients. According to Center
for International Blood & Marrow Transplant Research (2005), clinicians have la-
beled aGVHD as no-evidence clinical aGVHD, therapy-responsive aGVHD, therapy-
dependent aGVHD, and progressive aGVHD. Moreover, based on clinical symptoms,
aGVHD can be also classified into four severity phases, according to the two major
systems used for grading aGVHD, IBMTR and Glucksberg grading system. Thus,
in this study, we will assume the patients come from four latent aGVHD groups,
which equals the true inherent number of latent aGVHD groups in the simulated
data. More discussions on choosing the number of latent classes based on the model
selection results can be found in Chapter V.
One distinctive feature of aGVHD data is that a subset of patients are “aGVHD-
free.” Based on the clinical properties of allogeneic bone marrow transplantation
(BMT) and disease definition, patients who have not developed aGVHD within 100
days after BMT are assumed to never develop aGVHD. Thus, we classify all pa-
tients who have not experienced aGVHD within the first 100 days after BMT in the
“aGVHD-free” latent class.
The rest of this chapter is organized as follows. First, we introduce how to do
model fitting and prediction in JMLC. Next, we talk about the modeling fitting and
prediction of aGVHD in landmark analysis, followed by the metrics for evaluating
aGVHD predictions. Simulations under different scenarios are executed to check the
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prediction performance of these two methods under various scenarios. We conclude
with a brief discussion.
2.2 Joint Modeling with Latent Class
2.2.1 Model Setting
JMLC is proposed to model outcomes of various types, especially when there is no
closed-form for the joint distribution for these outcomes. In aGVHD data, the out-
come is a combination of repeated biomarker observations and times-to-aGVHD, and
we assume the distributions of biomarkers and times-to-aGVHD are different across
latent risk groups of aGVHD. To establish JMLC, we first define some notations used
throughout this section.
Let zi = (zi1, zi2, zi3, zi4)
′
represent the unobserved indicator vector of subject i’s
latent class membership, where zih = 1 if subject i belongs to latent class h, and 0
otherwise, for h = 1, 2, 3, and 4. Here we fix zi1 as the indicator of the aGVHD-
free latent class. Let pii = (pii1, pii2, pii3, pii4)
′
be the corresponding probabilities, and
pi = (pi1, pi2, pi3, pi4)
′
be the marginal probabilities of one subject belonging to each
aGVHD class, with the restriction that
∑4
h=1 pih = 1.
For the longitudinal biomarker process, we define Y i = (Yi(t1), Yi(t2), · · · , Yi(tni))
as the biomarker history of subject i at times (t1, t2, · · · , tni), where ni is the total
number of biomarker observations for subject i, for i = 1, 2, · · · , n. We assume the
biomarker data are collected according to a medical protocol based on the features
of aGVHD and time feasibility. Therefore, the timing of biomarker screening is un-
related to patients health conditions, or more specifically, patients’ biomarker levels.
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We specify that patients from the same latent class of aGVHD share the same
mean biomarker trajectory, with individual-specific random effects bi reflecting the
deviation of an individual’s biomarker pattern from the mean of their latent class.
The measurement error ei = (ei(t1), ei(t2), · · · , ei(tni)) of biomarkers introduces the
random noise in biomarker measurement. We assume the observed biomarkers, Yi,
random effects, bi, and measurement error, ei, Bi
′ = (Yi, bi, ei) given zih = 1 have a
multivariate normal distribution, i.e.
Bi|zih = 1 ∼MVN
(
Xiβ
(h)
0
0
 ,

ZiDZ
T
i + σ
2Ini ZiD σ
2Ini
DZTi D 0
σ2Ini 0 σ
2Ini

)
(2.1)
with a density function fh(Bi), where Xi is the design matrix including functions of
time, β(h) is the corresponding parameters of the mean biomarker trajectory in the la-
tent class h, Zi is design matrix of random effects that can be any subset ofXi, D is the
covariance matrix of the random effects that is constant among all latent classes, and
σ2 is the common variance of each element of ei. Let ω = (β
(1),β(2),β(3),β(4), D, σ2)
denote all the parameters involved in the longitudinal process.
For the time-to-aGVHD process, let Ti denote the observed time for subject i,
which is the minimum of time-to-aGVHD for subject i, T ∗i , and last follow-up time
Si. We also define δi as the indicator of whether subject i experiences aGVHD
(δi = 1) or is censored (δi = 0). For the “cured” latent class, the hazard of aGVHD
is 0 and the aGVHD probability is 0. For simplicity, we assume a Weibull distribu-
tion for the time-to-aGVHD of the three other latent classes, i.e., Pr(Ti > t|i ∈ h) =
exp(−(t/λ(h))κ(h)), with hazard function g(h)(t) = k(h)/λ(h)(t/λ(h))(κ(h)−1)exp(−(t/λ(h))κ(h)),
for h = 2, 3 and 4. Here we define ζ = (λ = (λ(2), λ(3), λ(4)),κ = (κ(2), κ(3), κ(4))) to
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be the parameters involved in the time-to-aGVHD process.
Let ξ = (pi,ω, ζ) represent the complete parameter set; the complete data are
(Yi, bi, Ti, δi, zi). The complete data likelihood function is:
L(ξ|Y , b, T, δ, z) =
n∏
i=1
[
[pi1f1(Bi|w)]zi1
4∏
h=2
[pihfh(Bi|w)(g(h)(Ti))δiexp(−
( Ti
λ(h)
)κ(h)
)]zih
]
with corresponding log-likelihood:
l(ξ|B, T, δ, z) = l1(pi|B, T, δ, z) + l2(ω|B, T, δ, z) + l3(ζ|B, T, δ, z) (2.2)
where l1(pi|B, T, δ, z) =
n∑
i=1
4∑
h=1
zihlog(pih), l2(ω|B, T, δ, z) =
n∑
i=1
4∑
h=1
zihlogfh(Bi|ω),
and l3(ζ|B, T, δ, z) =
n∑
i=1
4∑
h=2
zih[δilog(g
(h)(Ti)) − (Ti/λ(h))κ(h) ], which are the three
components of the log-likelihood corresponding to pi, ω and ζ. Because we cannot ob-
serve the individual-level latent class indicator zi in practice, we use the Expectation-
Maximization (EM) algorithm to find the expectation of unobserved zi and maximum
likelihood estimate (MLE) of parameters iteratively. Section 2.2.2 describes the de-
tails of using the EM algorithm to maximize the aforementioned log-likelihood in
Equation 2.2.
2.2.2 Parameter Estimation with the EM Algorithm
In the E-step, at iteration q + 1, we estimate the expectation of unobserved
complete-data sufficient statistics, (zi, bib
′
i, eie
′
i), conditionally on the parameter es-
timates ξ(q) from the previous iteration q. Here E(zi|ξ(q),Yi, Ti, δi) = piih(ξ(q)) is
the probability subject i at iteration q + 1 belongs to latent class h. For simplic-
ity, throughout the rest of subsections 2.2.2 and 2.2.3 we will use ξ instead of ξ̂(q)
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to represent the parameter estimation at iteration q. For the cases with observed
times-to-aGVHD, piih(ξ) is computed as:
piih(ξ) =
pihfh(Yi|ω)(gh(Ti))δiexp(−(t/λ(h))κ(h)∑4
l=2 pilfl(Yi|ω)(gl(Ti))δiexp(−(t/λ(l))κ(l))
(2.3)
for h = 2, 3, and 4. The value of pii1(ξ) for aGVHD-free patients is fixed at 1.
Next, we compute the expectation of bib
′
i and eie
′
i. Define H = ZiDZ
′
i + σ
2Ini ,
and given the joint distribution of Bi we obtain:
E(bib
′
i|Yi, ξ) = Ebi|Yi(bi|Yi)Ebi|Yi(bi|Yi)
′ + covbi|Yi(bi|Yi)
E(eie
′
i|Yi, ξ) = Eei|Yi(ei|Yi)Eei|Yi(ei|Yi)
′ + tr{covei|Yi(ei|Yi)}
where Ebi|Yi(bi|Yi) = DZiH
−1(Yi −Xiβ(h))
covbi|Yi(bi|Yi) = D −DZiH
−1ZiD
Eei|Yi(ei|Yi) = σ
2H−1(Yi −Xiβ(h))
covei|Yi(bi|Yi) = σ
2(Ini − σ2H−1)
With the complete data sufficient statistics (zi, bib
′
i, eie
′
i), we can compute the
three components, l1(pi|B, T, δ, z), l2(ω|B, T, δ, z), and l3(ζ|B, T, δ, z), in the expec-
tation of log-likelihood in Equation 2.2. In the M-step, we can compute the MLE
for parameters ξ = (pi,ω, ζ) by maximizing the corresponding expectation of the
log-likelihood. The MLE for the parameters in the longitudinal biomarker process,
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ω, are:
D̂ =
1
n
n∑
i=1
4∑
h=1
piih(ξ)
[
Ebi|Yi(bi|Yi)Ebi|Yi(bi|Yi)
T + covbi|Yi(bi|Yi)
]
σ̂2 =
1∑n
i=1 ni
n∑
i=1
4∑
h=1
piih(ξ)
[
Eei|Yi(ei|Yi)Eei|Yi(ei|Yi)
T + tr{covei|Yi(ei|Yi)}
]
β̂(h) =
[ n∑
i=1
piih(ξ)X
T
i Hi
−1Xi
]−1[ n∑
i=1
piih(ξ)X
T
i Hi
−1Yi
]
The MLE of ζ, the parameters in the time-to-aGVHD process, can be estimated
by maximizing E(l3(ζ|B, T, δ, z)). Since there is no closed form for the MLE, we will
use Newton’s method to find the MLE iteratively. Moreover, several existing packages
in R offer model fitting procedures for survival data with weights (Therneau, 2015).
The MLE of pi is pih =
∑n
i=1 piih(ξ)/n.
2.2.3 Prediction of Time-to-aGVHD
A patient receiving HSCT is scheduled to have serum drawn each week from
which biomarkers are measured. This procedure continues until this patient devel-
ops aGVHD or reaches 100 days without aGVHD. The prediction of aGVHD onset
is made after we obtain two biomarker observations, and this prediction is updated
every week when a new biomarker observation is available.
At week k, we obtain biomarker values Ym(k) = (Ym1, Ym2, · · · , Ymk) of a new
patient m, who inherently is aGVHD-free before week k. The probability that patient
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m will not develop aGVHD for the next two weeks is:
Pr(Tm > k + 2|Tm > k) =
4∑
h=2
Pr(zmh = 1|Ym(k))Pr(Tm > k + 2|Tm > k,m ∈ h) +
Pr(zm1 = 1|Ym(k))
where Pr(zmh = 1|Ym(k)) = pihfh(Ym|ω)P (Tm > k|m ∈ h, ζ)∑4
l=2 pilfl(Ym|ω)P (Tm > k|m ∈ l, ζ)
,
and Pr(Tm > k|zm1 = 1) = 1 for any k. So the probability of not developing
aGVHD in the next two weeks is the probability of patient m falls into aGVHD-free
class, plus a weighted sum of probabilities of not developing aGVHD for the next two
weeks, with weights equal to the probability that patient m belongs to each risk class.
2.3 Landmark Analysis
2.3.1 Model Setting
In a landmark analysis, a series of fixed times s = (s1, s2, · · · , sR) after HSCT are
selected as the landmark times. Unlike JMLC, which fits one overall model with all
the available data, landmark analysis updates the risk set and fits a separate model
at each landmark time. We ignore the patients who have developed aGVHD or been
censored before the landmark time. For patients developing aGVHD after the land-
mark time, we ignore biomarkers measured after the landmark time. A natural choice
of landmark time here would be the weekly biomarker screening day, because that is
when the biomarker information is updated, and the timing of biomarker screening
is independent of patients’ current or past biomarker levels.
As in Section 2.2, we define Y i = (Yi(t1), Yi(t2), · · · , Yi(tni)) to be the biomarker
history of subject i at times (t1, t2, · · · , tni), where ni is the total number of biomarker
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observations for subject i, for i = 1, 2, · · · , n. Let Ti denote the observed time for
subject i, which is the earlier of the time-to-aGVHD for subject i, T ∗i , and the last
follow-up time, Si. We also define δi as the indicator of whether subject i experiences
aGVHD (δi = 1) or is censored (δi = 0). Since the biomarker observations of all
patients are balanced and equally spaced at each landmark time, we can cluster the
samples without specifying the functional form of the biomarker trajectory, possibly
avoiding biased results caused by model misspecification.
Instead, we assume these biomarker observations are from a mixture of multi-
variate normal distributions, with the mixture defined by the membership in each
aGVHD risk class. Define vr as the number of biomarker samples by landmark time
sr. The distribution of biomarkers Yi = (Yi1, Yi2, · · · , Yi,vr) for subject i who is still
at risk for aGVHD is:
Yi ∼
4∑
h=1
pi
(sr)
h N (µh(sr),Σ(sr)h ) (2.4)
where µh
(sr) = (µh1, µh2, · · · , µh,vr) is the mean profile of biomarkers in class h
at landmark time sr, Σ
(sr)
h is the corresponding variance-covariance matrix, and
pi(sr) = (pi
(sr)
1 , pi
(sr)
2 , pi
(sr)
3 , pi
(sr)
4 ) is the marginal probabilities of a patient belonging
to each class at landmark time sr. In a landmark analysis, we allow the marginal
probabilities of class membership pi change along landmark time s.
Additional assumptions on µh
(sr) and Σ
(sr)
h can be made to reduce the number of
parameters to estimate. For example, in this study we assume Σ
(sr)
h = Σ
(sr) across
all classes. Moreover, one can assume an AR(1) structure of covariance between
biomarkers from the same subject. For simplicity, through the rest of this subsection
we will omit the superscript of landmark time sr.
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Because the patients at risk for aGVHD are updated at each landmark time, the
mean and variance-covariance of biomarkers are updated at each landmark time. The
likelihood for the parameters ξ = (µ,Σ,pi) at landmark time sr is:
L(sr)(ξ|Y, z) =
Nsr∏
i=1
4∏
h=1
{pih|Σ|− 12 exp(−1
2
(Yi − µh)′Σ−1(Yi − µh))}zih
where zi = (zi1, zi3, zi4, zi4)
T represents the indicator vector of subject i’s latent class
membership, and Nsk is number of patients at risk at landmark time sk. The corre-
sponding log-likelihood of ξ is:
l(sr)(ξ|Y, z) =
Nsr∑
i=1
4∑
h=1
[
zihlog(pih)− zihlog(|Σ|)
2
− zih
2
(Yi − µh)′Σ(sk)−1(Yi − µh)
]
(2.5)
The group indicator of each individual, zi, is unobservable, so we will employ the
EM algorithm iteratively to compute the expectation of zi and the MLE of ξ at each
landmark time sr. We will describe the details of using the EM algorithm to compute
the MLE of ξ in subsection 2.3.2.
2.3.2 Parameter Estimation with the EM Algorithm
At iteration q and in the E-step, the expectation of zih is calculated as:
piih(ξ
(q)) =
pi
(q)
h exp(−12(Yi − µh(q))′Σ−1(q)(Yi − µh(q)))∑4
l=1 pi
(q)
l exp(−12(Yi − µl(q))′Σ−1(q)(Yi − µl(q)))
(2.6)
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Then in the M-step, by maximizing the expectation of the log-likelihood as in Equa-
tion 2.5, we achieve the MLE of ξ = (µh,Σ,pi) as:
pih =
1
Nsr
Nsr∑
i=1
piih(ξ̂
(q))
µ̂h =
∑Nsr
i=1 piih(ξ̂
(q))Yi∑Nsr
i=1 piih(ξ̂
(q))
Σ̂ =
∑Nsr
i=1
∑4
h=1 piih(ξ̂
(q))(Yi − µ̂qh)(Yi − µ̂qh)′
Nsr
(2.7)
When convergence criteria are met, we achieve a set of parameter estimates of ξ̂ =
(µ̂h, Σ̂, p̂i), as well as the individual probability of belonging to each risk class pii =
(pii1, pii2, pii3, pii4).
Since landmark analysis ignores all the biomarkers observed after the landmark
time, the accuracy of long-term prediction is reduced. In practice, we will report
two-week prediction of aGVHD onset, so we will explore the two-week onset rate of
aGVHD in the model fitting stage.
We recode the time-to-aGVHD into an indicator Wi, representing whether or
not this individual experiences aGVHD within the next two weeks, with Wi = 1
representing aGVHD onset and Wi = 0 representing no aGVHD. We assume the
probability of experiencing aGVHD follows a binomial distribution. The logit of this
probability for patients in risk group h is modeled as:
log
(
Pr(Wi = 1|zih = 1)
1− Pr(Wi = 1|zih = 1)
)
= αh (2.8)
where α = (α(1), α(2), α(3), α(4)) denotes the marginal log odds ratio of developing
25
aGVHD in two weeks in each aGVHD latent class. The log-likelihood of α is:
l(α|W ,pii) =
4∑
h=1
( Nsr∑
i=1
piih[α
(h)Wi − log(1 + exp(α(h)))]
)
(2.9)
Then we can obtain the MLE of α by maximizing Equation 2.9. However, there is
no closed form for the MLE of α from Equation 2.9, so we will use Newton’s method
and get the MLE iteratively.
2.3.3 Prediction in Landmark Analysis
At week k, we want to make a prediction of aGVHD onset for a new patient m,
who has biomarker observation history Ym(k) = (Ym1, Ym2, · · · , Ymk), and the patient
m is inherently aGVHD-free before week k. The probability of being aGVHD-free for
the next two weeks is:
Pr(Tm > k + 2|Tm > k) =
4∑
h=1
pimh
exp(α̂h)
1 + ̂exp(αh)
(2.10)
where pimh =
pihexp(−12(Ym − µ̂h)′Σ̂−1(Ym − µ̂h))∑4
l=1 pilexp(−12(Ym − µ̂l)′Σ̂−1(Ym − µ̂l))
The MLE of parameters (ξ,α) achieved at landmark time sk are used in Equation
2.10.
2.4 Evaluation of Prediction
The evaluation of prediction falls into two fields, discrimination and calibration.
Discrimination indexes measure how well the model distinguishes between patients
who experience aGVHD from patients who do not experience aGVHD (Schoop et al.,
2011; Blanche et al., 2015; Yang et al., 2016; Rizopoulos et al., 2017). Calibration
indexes evaluate how accurate the model predicts the probability of aGVHD (Schoop
et al., 2011; Rizopoulos et al., 2017).
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In our simulation study, we will evaluate the prognosis of aGVHD onset at each
prediction time with both Brier Score (BS) and area under the curve (AUC). BS
assesses the absolute accuracy of predictions, and it has been widely used in evaluation
of prediction performance in survival analysis (Brier, 1950; Schemper and Henderson,
2000; Henderson et al., 2002; Rizopoulos et al., 2017). In our study, we define the
two-week BS at week k as:
BS(k) =
Nk∑
i=1
(Ii(k + 2)− Pri(k + 2))2 (2.11)
where Nk is the number of patients at risk at week k , and Ii(k + 2) and Pri(k + 2)
are the respective indicator of aGVHD status and predicted probability of aGVHD
at week k + 2 for patient i. Lower values of BS indicate better prediction, with a
perfect prediction indicated by BS = 0.
Alternatively, we use a receiver operating characteristic (ROC) curve to evaluate
the discrimination ability of our models. For each cut-off point of predicted proba-
bilities, the resulting sensitivity and specificity are indicated as a point on the curve.
The AUC is introduced to summarize the overall discrimination performance of a
prediction model, with a value of 0.5 indicating no predictive ability and a value of 1
indicating a perfect discrimination.
2.5 Simulation and Result
We speculate that several factors might influence the relative performance of
JMLC and landmark analysis. The first factor of practical interest is the overlap
of time-to-aGVHD distributions between latent classes. The second factor is the
size of biomarker measurement error. The third factor is the assumed functional
27
form of the biomarker patterns over time. In order to examine the effects of these
three factors, we generate more or less overlapping distributions of time-to-aGVHD
between latent classes, add large or small measurement errors to biomarker observa-
tions, and assume a linear trajectory of biomarkers over time or other irregular forms.
In our simulations, biomarker screening is scheduled right after HSCT (baseline)
and weekly thereafter until the onset of aGVHD. An uninformative baseline biomarker
level is assumed, so at least two biomarker observations are needed to make a predic-
tion for aGVHD onset. In each simulation, a sample of 200 patients is generated as
the training dataset, and another sample of 200 patients from the same population is
generated as the testing dataset. This population consists of subjects from four latent
classes: aGVHD-free, low-risk, medium-risk, and high-risk. Patients within the same
latent class share the same distribution of time-to-aGVHD and mean biomarker pro-
file. With each testing dataset, predictions are made at week 1, 2, · · · , 8 of aGVHD
onset within the next two weeks. We start from the end of week 1 because this is
when two biomarker observations are available for each patient, and we end at week 8
because a majority of aGVHD incidence occurs within 10 weeks of HSCT. The results
are based on 5,000 simulations.
2.5.1 Effect of Overlap in Time-to-aGVHD Distributions between Latent
Classes
First, we examine the impact of overlap in times-to-aGVHD between latent classes.
This overlap reflects the variance of the times-to-aGVHD in each latent class. If
there is less overlap of times-to-aGVHD between latent classes, patients with simi-
lar biomarker patterns are more likely to have similar times-to-aGVHD. Thus, the
distribution of times-to-aGVHD in one latent class, in which patients share same
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biomarker pattern, is concentrated. Otherwise, if there is extensive overlap of the
time-to-aGVHD distributions between latent classes, it is hard to tell one patient’s
latent class membership given only his/her biomarker profile.
We simulate data from two degrees of overlap in time-to-aGVHD distribution, as
demonstrated by Figure 2.1. When there is less overlap in time-to-aGVHD distri-
Figure 2.1: Time-to-aGVHD distributions for three risk classes: 1. blue; 2. red;
3. black (left: less overlap of times-to-aGVHD; right: more overlap of
times-to-aGVHD)
butions, as shown in the left panel in Figure 2.1, times-to-aGVHD are more distinct
between latent classes. For example, at week 4, the majority of aGVHD cases come
from latent class 1. On the other hand, when there is more overlap in time-to-aGVHD
distributions, as shown in the right panel in Figure 2.1, the aGVHD cases at week 4
come from all three risk classes.
We start with a visualization of the different datasets generated with less or more
overlap in times-to-aGVHD. A dataset of 200 patients is generated in each scenario,
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and the biomarker observations of these patients are shown in Figure 2.2. According
Figure 2.2: Simulated biomarker observations of 200 patients (top: less overlap of
time-to-aGVHD distributions; Bottom: more overlap of time-to-aGVHD
distributions)
to Figure 2.2, when there is more overlap of times-to-aGVHD between latent classes
(shown in the bottom), the distribution of times-to-aGVHD among patients with
similar biomarker trajectories is dispersive.
Table 2.1 summarizes the AUCs and BSs of prediction at weeks 1, 2, · · · , 8. Both
JMLC and landmark analysis do a better job in distinguishing patients with vari-
ous risk, and providing a more accurate prediction of aGVHD onset, when there is
less overlap of time-to-aGVHD distributions between latent classes in contrast to the
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Table 2.1: Mean (SD) of BSs and AUCs of 5,000 simulations with two degrees of
overlap in time-to-aGVHD distributions
Prediction made at (week) 1 2 3 4 5 6 7 8
Less overlap of time-to-aGVHD distributions between latent classes
AUC
JMLC
0.859 0.984 0.918 0.925 0.988 0.907 0.857 0.993
(0.042) (0.009) (0.026) (0.015) (0.007) (0.028) (0.035) (0.010)
LM
0.942 0.971 0.874 0.908 0.968 0.867 0.822 0.973
(0.019) (0.022) (0.037) (0.022) (0.033) (0.053) (0.046) (0.018)
BS
JMLC
0.158 0.155 0.073 0.132 0.086 0.114 0.153 0.035
(0.012) (0.015) (0.014) (0.030) (0.039) (0.014) (0.029) (0.020)
LM
0.090 0.062 0.080 0.103 0.063 0.115 0.158 0.059
(0.020) (0.026) (0.015) (0.016) (0.039) (0.030) (0.021) (0.022)
More overlap of time-to-aGVHD distributions between latent classes
AUC
JMLC
0.817 0.923 0.918 0.915 0.895 0.876 0.914 0.971
(0.064) (0.019) (0.017) (0.025) (0.025) (0.031) (0.031) (0.020)
LM
0.871 0.893 0.872 0.873 0.857 0.829 0.879 0.954
(0.034) (0.023) (0.036) (0.041) (0.037) (0.051) (0.041) (0.026)
BS
JMLC
0.149 0.156 0.138 0.134 0.135 0.138 0.108 0.059
(0.018) (0.031) (0.027) (0.026) (0.017) (0.017) (0.026) (0.025)
LM
0.103 0.118 0.137 0.137 0.144 0.157 0.130 0.080
(0.012) (0.015) (0.018) (0.023) (0.021) (0.021) (0.021) (0.026)
more overlap scenario. This is because in the less overlap scenario, times-to-aGVHD
are more distinct between latent classes. Therefore, JMLC, in which a patient’s time-
to-aGVHD contributes to the latent class identification, results in a better prediction
of one’s latent class membership, and thus produces a more accurate aGVHD predic-
tion. On the other hand, landmark analysis, in which the latent class membership
only depends on the biomarkers, also achieves more accurate aGVHD prediction be-
cause the variance of times-to-aGVHD in each latent class is small.
In both the less and more overlap scenarios, JMLC better distinguishes patients
who will experience aGVHD in the next two weeks, with higher AUCs starting from
week 2. This is because the discrimination ability depends mainly on accurately
identifying the latent class membership. JMLC, which incorporates a patient’s time-
to-aGVHD to the latent class prediction, has more accurate predictions of latent class
membership than landmark analysis, thus, it has higher AUCs. However, when we do
prediction at week 1, JMLC is inferior to landmark analysis. This is because everyone
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is aGVHD-free until week 1, so the fact that a patient is aGVHD-free by week 1 does
not contribute to the prediction of latent class membership. Moreover, in contrast to
JMLC, landmark analysis uses only the available biomarker observations before the
landmark time to fit a model. Thus, it avoids interpreting the noise associated with
later biomarkers and has a better AUC than JMLC, when we make a prediction at
week 1.
For both simulation scenarios with either less or more overlap of times-to-aGVHD,
the prediction accuracy of JMLC is inferior to landmark analysis when only a few
biomarker observations are available, reflecting larger BSs. This is because landmark
analysis ignores all the biomarker observations and time-to-aGVHD after the land-
mark time, and thus avoids interpreting the noise associated with future observations.
However, when more biomarker observations are collected, JMLC shows better pre-
diction accuracy than landmark analysis in terms of lower BSs. This accuracy gap
becomes more obvious when there is more overlap of times-to-aGVHD between latent
classes. This is because at each landmark time, we still fix the number of latent classes
of aGVHD at four, which, according to Figure 2.2, is not a correct assumption in the
later post-HSCT period. For example, after week 7, the majority of patients are from
only two latent classes of aGVHD. Assuming the patients are from four latent classes
will over-fit the training dataset, and thus result in poor prediction performance.
We also find that landmark analysis is more sensitive than JMLC to the degree of
overlap in time-to-aGVHD distributions. This is because landmark analysis builds a
model only on the subset of patients who are still at risk at each landmark time. When
there is less overlap in times-to-aGVHD between latent classes, the risk set changes
dramatically at different landmark times. JMLC, however, fits a model on the whole
dataset, incorporating both patients’ biomarker history and times-to-aGVHD. Thus,
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it is more robust to the change of overlap in time-to-aGVHD distributions.
In this subsection, we have compared the prediction performance of JMLC and
landmark analysis, in terms of discrimination and accuracy, under less overlap and
strong overlap of times-to-aGVHD scenarios. If we compare the AUCs of JMLC
across prediction times, we do not find a clear trend and the AUCs fluctuate. Simply
comparing AUCs across time is not recommended because there are different patients
at risk at each prediction time. In Table 2.1, we present AUCs calculated with a
cumulative sensitivity and a dynamic specificity (Heagerty and Zheng, 2005). The
interpretation of cumulative sensitivity is straightforward: that among all the pa-
tients at risk at time s, whoever develop the event between (s, s + t∗) are labeled as
cases, where s is the prediction time, and t∗ is the prediction window. We adopt a
dynamic specificity, because the patients in the “control” set at time s might join the
“aGVHD-cases” later, so the later the prediction time s is, the fewer the patients in
the control set. With a dynamic specificity, the AUC highly depends on the distri-
bution of time-to-aGVHD, and thus it is inappropriate to compare AUCs across time.
As shown in Table 2.1, in the less overlap scenario, the AUC of JMLC at week 2, 5,
and 8 are relatively high, compared with other prediction times. This matches what
we see in the left panel in Figure 2.1. At week 4, 7, and 10, the majority of aGVHD
cases come from one latent class, and nearly all the aGVHD-free patients come from
the other latent classes. Therefore, the 2-week predictions at week 2, 5 and 8 achieve
higher AUCs. On the other hand, we do not see the same pattern of AUCs of JMLC
in the more overlap scenario. This is because at week 4, 7, and 10, the aGVHD cases
could be from all the risk latent classes, and the aGVHD-free patients could also be
from all latent classes. Thus, we do not recommend comparing AUCs across time.
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For the remaining two settings, we will simulate data from the less overlap scenario,
and explore the effects of measurement error and model mis-specification.
2.5.2 Effect of Biomarker Measurement Error
Second, we focus on comparing the relative performance of JMLC and landmark
under two degrees of measurement error. The explanation of certain patterns in AUCs
and BSs that are caused by the less overlap time-to-aGVHD distributions between
latent classes are omitted in this subsection.
We randomly generate two datasets of 200 patients with large and small biomarker
measurement errors, as demonstrated in Figure 2.3.
Table 2.2 summarizes the AUCs and BSs of aGVHD prediction at week 1, 2, · · · ,
and 8. When the measure error is small, both JMLC and landmark analysis better
distinguish patients in high risk of aGVHD and provide more accurate prediction of
aGVHD onset, compared with the scenario with large measurement error. However,
this superiority is alleviated when more biomarker observations are available at the
prediction time. This is because when more biomarker observations are available,
both models have more power to eliminate the effect of the measurement error and fit
the model with the true biomarker values. Thus, the size of the measurement error
does not affect the results when more biomarker observations are available.
When the measurement error is large, JMLC does better than landmark analysis
in identifying patients who will experience aGVHD in two weeks when more than two
biomarker observations are available. When the measurement error is small, JMLC
also better distinguishes patients who will experience aGVHD in two weeks, with
higher AUCs at all prediction times than landmark analysis.
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Figure 2.3: Simulated biomarker observations of 200 patients (top: large (sd = 1)
measurement error; Bottom: small (sd = 0.5) measurement error)
When the measurement error is large, the absolute prediction accuracy of JMLC
is inferior when there are only two or three biomarker observation available, reflecting
larger BSs than landmark analysis. When more biomarker observations are collected,
JMLC and landmark analysis perform equally well in terms of BSs; and JMLC does
perform better than landmark analysis for later predictions when more than eight
biomarker observations are available. In the small measurement error scenario, we
observe the same trend in BSs as that in the large measurement error scenario.
When we compare between simulations with large and small measurement errors,
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Table 2.2: Mean (SD) of BSs and AUCs of 5,000 simulations with two measurement
errors of biomarkers
Prediction made at (week) 1 2 3 4 5 6 7 8
large measurement error (sd = 1)
AUC
JMLC
0.859 0.984 0.918 0.925 0.988 0.907 0.857 0.993
(0.042) (0.009) (0.026) (0.015) (0.007) (0.028) (0.035) (0.010)
LM
0.942 0.971 0.874 0.908 0.968 0.867 0.822 0.973
(0.019) (0.022) (0.037) (0.022) (0.033) (0.053) (0.046) (0.018)
BS
JMLC
0.158 0.155 0.073 0.132 0.086 0.114 0.153 0.035
(0.012) (0.015) (0.014) (0.030) (0.039) (0.014) (0.029) (0.020)
LM
0.090 0.062 0.080 0.103 0.063 0.115 0.158 0.059
(0.020) (0.026) (0.015) (0.016) (0.039) (0.030) (0.021) (0.022)
small measurement error (sd = 0.5)
AUC
JMLC
0.967 0.997 0.930 0.932 0.989 0.904 0.853 0.988
(0.014) (0.004) (0.025) (0.017) (0.008) (0.030) (0.034) (0.054)
LM
0.964 0.980 0.884 0.915 0.968 0.866 0.826 0.977
(0.015) (0.028) (0.035) (0.023) (0.038) (0.047) (0.038) (0.018)
BS
JMLC
0.154 0.124 0.069 0.103 0.054 0.110 0.155 0.026
(0.013) (0.026) (0.012) (0.024) (0.031) (0.014) (0.030) (0.021)
LM
0.065 0.043 0.077 0.099 0.059 0.110 0.156 0.054
(0.017) (0.029) (0.017) (0.016) (0.042) (0.028) (0.017) (0.024)
we find that increasing measurement error in biomarkers weakens the prediction ac-
curacy for both JMLC and landmark analysis, resulting in lower AUCs and larger
BSs. However, this negative impact attenuates at later post-HSCT predictions.
2.5.3 Effect of Model Specification
A main feature of landmark analysis is that we avoid specifying any functional
form of biomarker trajectories, but assume a multivariate normal distribution of
biomarkers. Thus, we want to evaluate the impact of model misspecification on
JMLC, especially when JMLC chooses a basic functional form to describe how biomark-
ers change over time. Figure 2.4 presents one example of simulated patients’ dataset,
with biomarkers changing non-linearly over time, and the functional forms various
across latent classes of aGVHD.
According to the dataset presented in Figure 2.4, assuming that biomarkers change
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Figure 2.4: Simulated biomarker observations of patients from four latent risk classes
of aGVHD, with biomarkers changing unlinearly over time
linearly over time is specious. We fit two separate models to this dataset, one is land-
mark analysis, and the other is a JMLC with biomarkers changing linearly after BMT.
The results of 5,000 simulations are shown in Table 2.3.
When biomarker observations change non-linearly over time, there is a noticeable
decrease in the prediction performance of JMLC, reflecting reduced AUCs and in-
flated BSs. Landmark analysis, on the other hand, provides consistent discrimination
ability and accuracy, regardless of how biomarkers change over time.
When biomarker observations change non-linearly over time, JMLC, compared
with landmark analysis, better distinguishes patients in high risk of aGVHD when
more than three biomarker observations are available. This is because JMLC in-
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Table 2.3: Mean (SD) of BSs and AUCs of 5,000 simulations with two functional
forms of biomarkers
Prediction made at (week) 1 2 3 4 5 6 7 8
Linear functional forms of biomarkers
AUC
JMLC
0.859 0.984 0.918 0.925 0.988 0.907 0.857 0.993
(0.042) (0.009) (0.026) (0.015) (0.007) (0.028) (0.035) (0.010)
LM
0.942 0.971 0.874 0.908 0.968 0.867 0.822 0.973
(0.019) (0.022) (0.037) (0.022) (0.033) (0.053) (0.046) (0.018)
BS
JMLC
0.158 0.155 0.073 0.132 0.086 0.114 0.153 0.035
(0.012) (0.015) (0.014) (0.030) (0.039) (0.014) (0.029) (0.020)
LM
0.090 0.062 0.080 0.103 0.063 0.115 0.158 0.059
(0.020) (0.026) (0.015) (0.016) (0.039) (0.030) (0.021) (0.022)
Non-linear functional forms of biomarkers
AUC
JMLC
0.523 0.964 0.841 0.814 0.909 0.868 0.849 0.990
(0.147) (0.019) (0.077) (0.126) (0.101) (0.057) (0.045) (0.052)
LM
0.944 0.978 0.692 0.792 0.898 0.820 0.836 0.995
(0.022) (0.020) (0.073) (0.107) (0.117) (0.102) (0.031) (0.009)
BS
JMLC
0.193 0.120 0.180 0.554 0.512 0.441 0.180 0.005
(0.101) (0.035) (0.036) (0.065) (0.076) (0.080) (0.043) (0.007)
LM
0.104 0.031 0.084 0.151 0.103 0.121 0.136 0.004
(0.021) (0.032) (0.020) (0.026) (0.059) (0.037) (0.014) (0.007)
corporates the aGVHD-free time into the latent class prediction, and thus it better
predicts the latent class membership than landmark analysis. This advantage offsets
the accuracy loss caused by model misspecification.
2.6 Discussion
In our study, landmark analysis is constructed to use all the biomarker informa-
tion up to the landmark time, and distinguishes patients of different risk classes of
aGVHD. In contrast to landmark analysis in other studies, where only the most re-
cent biomarker observation is used at each landmark time, the landmark analysis we
proposed have two benefits. First, we adjust for the measurement error of biomarkers.
As shown in Table 2.2, when we make the prediction with at least four biomarker ob-
servations, the size of measurement error does not affect the prediction performance
of landmark analysis. Second, our landmark analysis adjusts for the heterogeneity
among patients. Identifying sub-population in various risks is one of the primary
goal in practice, because clinicians could assign appropriate intervention according to
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patients’ risk status and thus avoid over-treatment.
The JMLC we proposed allows one specific latent class as the “cured” class, and it
could be applied in many other medical fields. For a few medical conditions, especially
chronic disease such as cancer, there is a nonnegligible “cured” fraction of patients
whose pathomechanism is distinct to that of susceptible patients. Thus, these “cured”
patients’ biomarker profiles are different than those of susceptible patients. Failing to
identify this “cured” class and treating these patients as censored will lead to biased
results, and might cause over-intervention with patients in little risk.
One primary difference between the two proposed methods is how time-to-aGVHD
is used to determine the latent class membership. In JMLC, we model the biomarker
process and time-to-aGVHD simultaneously, and use both biomarkers and times-to-
aGVHD to estimate the latent class each individual belongs to within the model
fitting process. In landmark analysis, we split the model fitting into two steps. In the
first step, we identify the class-level pattern of biomarkers and individual-level prob-
abilities of patients belonging to each latent class. In the second step, we estimate
the distribution of aGVHD in each latent class with the individual-level probabilities
as the weight of a patient belonging to a latent class. JMLC utilizes all the data
simultaneously and achieves high efficiency and accuracy when assumptions are met.
On the other hand, one major benefit of landmark analysis is that it allows flexible
parametrization for the biomarker process. As in our proposed landmark analysis, we
do not specify a functional form of how biomarkers change over time, and thus reduce
the risk of model misspecification. To reduce the bias of parameter estimation caused
by modeling biomarkers and times-to-aGVHD separately, the risk set is updated at
each landmark time.
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Based on the simulation results, JMLC on average shows better discrimination
ability on predictions, and more accurate prediction of probability of aGVHD when
there are many biomarker observations available. Landmark analysis, however, presents
good discrimination ability and prediction accuracy when there are only limited
biomarker observations. When predicting time-to-aGVHD in early post-HSCT pe-
riod, JMLC borrows biomarker information of patients who haven’t experienced
aGVHD beyond that time period, which may add more noise rather than increase
efficiency to the prediction. On the other hand, when predicting time-to-aGVHD in
late post-HSCT period, landmark analysis with fixed number of latent classes over-
trains the data and adds more noise to model fitting.
One limitation of this study is that both methods require a pre-specified number of
latent classes. We assume the population is a mixture of patients from four aGVHD
latent groups. Model selection on number of latent classes can be done based on
Bayesian information criterion(BIC) or deviance information criterion(DIC) (Proust-
Lima et al., 2014). However, we need to repeat the same model fitting process multiple
times to find an ideal number of latent classes, and the selection criteria is based on
model fitting performance rather than prediction. In this chapter, we avoid discussion
on choosing the best number of latent class, and we will address this issue in Chapter
V.
In this study, we did not consider competing risks of aGVHD in patients who
received HSCT. As introduced in Chapter 1.1, cancer recurrence, infection, and or-
gan failure are major causes of mortality of AML patients; these conditions, together
with death, are competing risks which either hinder the observation of aGVHD or
modify the chance that aGVHD occurs. In future work, we could consider scenarios
in which competing risks are present and times-to-aGVHD will be dependently cen-
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sored. In general, we could modify the survival sub-model in JMLC, and the logistic
model in landmark analysis, to incorporate these competing risks. Existing compet-
ing risk analysis methods could be used to replace the standard Cox regression model.
We also did not consider incorporating other covariates, such as conditioning
regimens, donor type, or previous treatment regimens. Nonetheless, our approach
is flexible enough to allow the additional modeling of covariates.
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CHAPTER III
Dynamic Prediction of Time-to-acute
Graft-versus-Host-Disease with Pattern Mixture
Model
3.1 Introduction
In the previous chapter, we modeled the association of longitudinal biomarkers
and time-to-aGVHD with both JMLC and landmark analysis. Both of the two meth-
ods require a pre-specified number of latent classes. One approach to select the best
number of latent classes is by model selection. A series of candidate number of latent
classes are chosen, and then a separate model is fitted with each number of latent
class. The final model is selected based on information based criteria, such as Akaike
information criterion (AIC) or Bayesian information criterion (BIC). However, there
are several limitations of this procedure. First it is computationally intensive because
a separate model is needed for each candidate number of latent classes. Moreover,
AIC and BIC are measures on overall model fitting, favouring smaller residuals in
the model while penalizing the number of predictors to avoid overfitting. As a re-
sult, AIC and BIC are not necessarily measuring prediction performance. In this
chapter, we aim to build a tractable but flexible model predicting the onset time of
aGVHD given longitudinal biomarker values. Like the methods in Chapter II , our
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new model should be able to reflect the varying risk levels of aGVHD, and update
the prediction of time-to-aGVHD when a new biomarker observation is available. In
contrast to Chapter II, we attempt to simplify model fitting and avoid the need for a
pre-specified number of latent classes.
In this chapter, we predict the time-to-aGVHD with the pattern mixture model.
The pattern mixture model has been applied to settings with missing data, and the
focus has been on its application to longitudinal data with monotone missingness.
The pattern mixture model stratifies the data by patterns of missingness, and then
models the differences in the distribution of longitudinal data over these patterns. In
our settings of aGVHD data, we propose fitting the pattern mixture model to the
longitudinal biomarkers, with patterns depending on the time-to-aGVHD. Consid-
ering a fictitious dataset with discrete times-to-aGVHD, i.e., there are only a few
unique times-to-aGVHD, it is plausible to form one pattern at each time-to-aGVHD,
assuming there are enough data at each unique time-to-aGVHD. In practice, we re-
measure the time-to-aGVHD in weeks, and round this time-to-aGVHD to the largest
next integer. For example, the time-to-aGVHD of a patient at day 24 will be recoded
as week 4. Then we assume patients with the same week of aGVHD share the same
biomarker trajectory pattern, and the aGVHD-free patients share another biomarker
trajectory pattern.
There are several reasons for why we choose to remeasure time-to-aGVHD in
weeks. First, this guarantees enough samples for model fitting in each pattern, re-
sulting in better efficiency for parameter estimation. Second, the precision of predic-
tion in weeks is well-accepted for clinicians. Moreover, weekly biomarker screening is
scheduled, so the prediction of aGVHD is updated weekly.
43
In Chapter II, we aimed to predict the onset of aGVHD in the next two weeks with
repeatedly collected biomarker observations. In this chapter, we would like to predict
the probability of aGVHD in the next week, the week after that, and so forth. In
other words, we achieve the whole distribution of future times-to-aGVHD (measured
in weeks). For this purpose, we introduce a new assessment of prediction, the Brier
Score (BS), which can evaluate the accuracy of prediction on the whole distribution
of future times.
The rest of this chapter is organized as follows. First, we introduce how to do
model fitting and make predictions with the pattern mixture model. Next, we describe
the two assessments we use to measure the performance of the prediction with the
pattern mixture model, followed by simulation results and discussion. A conclusion
is drawn at the end.
3.2 Pattern Mixture Model Fitting and Prediction
3.2.1 Notation
Define Ti to be the recorded time-to-aGVHD in weeks for subject i, which is the
minimum of the time-to-event for subject i, T ∗i , and last follow up time, Si. We also
define δi as the indicator of whether subject i experiences aGVHD (δi = 1) or is
censored (δi = 0). Given the properties of the simulated data, for all patients in the
aGVHD-free group, δi = 0; and for all patients not in aGVHD-free group, δi = 1.
We also define Y i = (Yi(t1), Yi(t2), · · · , Yi(tni)) as the biomarker history of subject
i at time (t1, t2, · · · , tni), where ni is the total number of biomarker observations for
subject i, for i = 1, 2, · · · , n.
For simplicity, we assume that the continuous biomarker observations change lin-
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early over time, but it is straightforward to generalize them as other functional forms
of time. Random effects bi = (b0i, b1i) are introduced to reflect the individual devi-
ation of the biomarker trajectories from the population mean. Thus, we assume the
biomarker observations, Yi, follow a multivariate Gaussian distribution with pattern-
specified mean profile:
Yi|Ti = XiβTi +Zibi + i (3.1)
where Xi and Zi are the design matrices for subject i with the first column all
1s and the second column the biomarker observation times, bi are random effects
with variance-covariance matrix D, i is the the measurement error which follows
a Gaussian distribution with mean 0 and variance σ2I, and βTi = (β0,Ti , β1,Ti)
′
is the fixed effects associated with the mean pattern profile. Define ξ = (βT =
(βT1 ,βT2 , · · · ,βTJ )′, D, σ2) as the parameters of interest, where J represents the
number of unique values of times-to-aGVHD. By fitting a linear mixed model with
time-to-aGVHD as a predictor, we obtain the MLE of ξ.
3.2.2 Prediction
The marginal distribution of observed biomarkers is a finite mixture of Gaussian
distributions, and the posterior probability of a new patient m developing aGVHD at
week j, with the observed biomarkers history by week k, Ym = (Ym1, Ym2, · · · , Ym,k),
is:
Pr(Tm = j|Ym, ξ) =
f(Ym|βTj , D, σ2)Pr(Tm = j)∑J
l=k f(Ym|βTl , D, σ2)P (Tm = l)
(3.2)
for j ≥ k. The biomarker observations Ym given time-to-aGVHD, Tj, follow a
multivariate normal distribution with mean XmβTj and variance-covariance matrix
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ZmDZ
′
m + σ
2I.
3.3 Predictive Accuracy Measures for Dynamic Predictions
Our first measure of predictive accuracy is the Brier Score (BS), which measures
the calibration of probabilistic predictions (Brier, 1950). In a multi-class setting, it
is defined as BS = 1
n
∑n
i=1
∑J
j=1(fij − oij)2, where fij is the forecasted probability of
subject i (i = 1, 2, · · · , n) belonging to the category j (j = 1, 2, · · · , J), and oij is the
actual outcome of subject i (1 if subject i belongs to category j, 0 otherwise). In a
case when there are 11 categories, the BS of a random guess is 10/11, and a perfect
prediction would achieve BS at 0. To make the BS comparable to another metric we
present later, we will subtract the BS from 1, so that a perfect prediction has BS =
1; a random prediction has BS close to 0.
In our study, we propose a dynamic BS, which is defined as:
BS(k) = 1− 1∑n
i=1 I(Ti ≥ k)
n∑
i=1
J∑
j=1
I(Ti ≥ k)[fij(Yi)− oij]2 (3.3)
which is the sum of squared prediction errors across all subjects who are still at risk
at the prediction time k. Note that the BS can be written as:
BS(k) = 1− 1∑n
i=1 I(Ti ≥ k)
n∑
i=1
J∑
j=1
I(Ti ≥ k)([fij(Yi)− E(oij)]2 + [E(oij)− oij]2)
= Bias2[fij] + Var[fij] (3.4)
Therefore, BS summarizes both the accuracy and uncertainty of the prediction.
Our second measure of the prediction accuracy is the dynamic prediction accuracy
rate (PAR). We define PAR at time k to be the proportion of accurate prediction
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given biomarker observations up to time k in patients who are at risk at time k, i.e.
PAR(k) =
∑n
i=1
∑J
t=k I(Ti = t)I(P (Ti = t) ≥ P (Ti = l) for any l 6= t)∑n
i=1 I(Ti ≥ k)
(3.5)
PAR will increase if we widen the windows of accuracy of prediction, perhaps by
including predictions that are one week earlier or later than the actual event time
only.
3.4 Simulation and Result
In this section we will simulate data under three settings: (1) a joint model with
eleven latent classes, (2) a joint model with four latent classes, and (3) a joint model
with four latent class and shared random effects. These three settings reflect different
fundamental assumptions on the relationship between time-to-aGVHD, biomarkers
and latent classes. Setting (1) assumes the latent class can be almost defined by
time-to-aGVHD, and vice versa. This implies that there are less overlappping in the
distributions of time-to-aGVHD of each pattern. Setting (2) adopts the same assump-
tions as setting (1) by assuming the patients are of varying latent classes of aGVHD,
and patients within one latent class share the same distribution of time-to-aGVHD.
However,unlike setting (1), in setting (2) patients in one latent class share a more
disperse distribution of time-to-aGVHD and biomarker trajectories. Patients have
similar biomarker trajectories may end up with obvious different times-to-aGVHD,
so it is hard to distinguish the latent class from each other just based on times-to-
aGVHD, compared with setting (1). Setting (3) considers that individual deviations
of biomarker trajectories also contribute to the variation of time-to-aGVHD within
each latent class. In other words, the fundamental assumption of conditional indepen-
dence of JMLC is violated, and both the latent classes and these individual deviations
contribute to the correlation between biomarkers and times-to-aGVHD.
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In all three simulation settings, biomarker screening is scheduled right after HSCT
(baseline) and weekly thereafter until the onset of aGVHD. An uninformative baseline
biomarker level is assumed, so at least two biomarker observations are needed to make
a prediction for the onset of aGVHD. For simplicity, we specify that the biomarkers
change linearly over time with measurement errors. Patients within one latent class
share the same mean intercept and slope of biomarkers, with individual deviations of
intercepts and slopes. In each simulation setting, we explore the performance of our
model under seven scenarios defined by the variance-covariance structure of individual
deviations of the intercept and the slope, as well as the variance of the measurement
error. The details of seven scenarios can be found in Table 3.1. Compared with
Scenario 1-3, biomarkers generated under Scenario 4-6 are more distinct between
patterns, given the smaller variance of deviation of biomarker trajectory. In contrast
with Scenario 4, Scenario 7 has a larger measurement error of biomarkers.
Table 3.1: Simulation scenarios with various covariance of random effects and vari-
ance of measurement error
Scenario V ar(b0i) Var(b1i) ρ(b0i, b1i) sd()
1 0.16 0.16 0 0.5
2 0.16 0.16 -0.5 0.5
3 0.16 0.16 0.5 0.5
4 0.0625 0.0625 0 0.5
5 0.0625 0.0625 -0.5 0.5
6 0.0625 0.0625 0.5 0.5
7 0.0625 0.0625 0 1
A series of prediction times are set weekly from week one until week ten, right after
biomarker screening. We run 1,000 simulations and compute the means and standard
deviations of the resulting BS and PAR at each future time s, where s = 1, 2, · · · , 10th
week. In each simulation setting, we compare the prediction accuracy of our model
with the theoretically best prediction that could be achieved. The latter is calculated
based on the “true” value of parameters, and reflects the variation of prediction even
48
when parameters of interest are correctly estimated. Through these comparisons, we
are able to quantify the loss of prediction accuracy caused by assigning latent class
membership solely on a patient’s time-to-aGVHD.
3.4.1 Simulation from Joint Model with Eleven Latent Classes
We start with simulation setting (1), where we simulate data from a joint model
with eleven latent classes. We choose eleven latent classes because we will group the
patients into eleven patterns according to the week they develop aGVHD. We assume
that the patients of each latent class share the same time-to-aGVHD distribution,
which is defined as a Weibull distribution. Two hundred patients are simulated as
the training dataset, and another 200 patients from same population are simulated as
the test dataset. In this population, around 5% subjects would most likely experience
aGVHD one week after BMT, another 15% might undergo aGVHD onset two weeks
after BMT, and so forth. The details of simulation parameters can be found in Table
3.2.
Table 3.2: Simulation parameters for joint modeling with eleven latent classes
Latent
Class
Population
Proportion
Time to aGVHD (Weibull) Biomarker Trajectory
λ κ Intercept Slope
1 5% 11.605 34 10 0
2 5% 10.604 31 10 1
3 5% 9.603 28 10 2
4 5% 8.601 25 10 3
5 5% 7.599 22 10 4
6 10% 6.596 19 10 5
7 10% 5.592 16 10 6
8 15% 4.594 14 10 7
9 20% 3.588 11 10 8
10 15% 2.577 8 10 9
11 5% 1.55 5 10 10
Although in this setting, the distributions of time-to-aGVHD in each pattern are
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concentrated, the simulated times-to-aGVHD can still take various values. Thus,
analyzing the data simulated from setting (1) with the pattern mixture model, we
might group patients from different latent classes into one pattern, so the biomarker
trajectory estimation of one latent class might be biased. This reflects the bias por-
tion of BS as shown in Equation 3.4. In other words, when using the pattern mixture
model to analyze data simulated from a joint model, BS contains bias due to grouping
patients based on the time-to-aGVHD only.
In order to quantify the accuracy loss of prediction by this bias, we calculate the
“true” probability of aGVHD under joint modeling with eleven latent classes as:
P (k + l ≤ Tm ≤ k + l + 1|Tm ≥ k,Y m,θ)
=
J∑
j=1
P (k + l ≤ Tm ≤ k + l + 1|Tm ≥ k, cm = j,θ)P (cm = j|Tm ≥ k,Y m,θ)
=
∑J
j=1 Pr(cm = j)f(Y m|cm = j,θ)[S(k + l|cm = j,θ)− S(k + l + 1|cm = j,θ)]∑J
j=1 Pr(cm = j)f(Y m|cm = j,θ)S(k|cm = j,θ)
(3.6)
where θ is the simulation parameters as listed in Table 3.2, Y m is the biomarker
observations history of subject m, and k is the prediction time.
Table 3.3 summarizes the mean BSs of the pattern mixture model, the “true”
model, and the mean and standard deviation of their difference. In each scenario,
the pattern mixture model has lower BSs relative to the “true” model. However,
compared with their standard deviations, these losses are not significantly different
from 0. Moreover, compared with the BS of the “true” model, pattern mixture model
losses approximate 5% of the BS.
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Table 3.3: Brier Score of the pattern mixture model under simulation setting (1)
Prediction at week 1 2 3 4 5 6 7 8 9 10
Scenario 1
True 0.384 0.511 0.571 0.585 0.582 0.607 0.597 0.614 0.653 0.726
PM 0.365 0.484 0.540 0.549 0.539 0.563 0.547 0.564 0.603 0.677
Difference (mean) 0.019 0.027 0.032 0.036 0.042 0.044 0.050 0.050 0.050 0.049
Difference (SD) 0.012 0.015 0.018 0.023 0.029 0.034 0.043 0.049 0.056 0.067
Scenario 2
True 0.415 0.563 0.618 0.626 0.622 0.644 0.627 0.644 0.676 0.750
PM 0.395 0.530 0.581 0.585 0.574 0.594 0.572 0.589 0.623 0.696
Difference (mean) 0.021 0.033 0.037 0.041 0.047 0.050 0.055 0.055 0.053 0.053
Difference (SD) 0.012 0.018 0.021 0.026 0.032 0.037 0.045 0.050 0.057 0.072
Scenario 3
True 0.365 0.490 0.558 0.580 0.584 0.615 0.603 0.627 0.663 0.739
PM 0.346 0.465 0.528 0.543 0.540 0.568 0.550 0.572 0.613 0.690
Difference (mean) 0.019 0.025 0.031 0.037 0.044 0.047 0.053 0.055 0.051 0.050
Difference (SD) 0.012 0.015 0.018 0.023 0.029 0.034 0.043 0.048 0.056 0.069
Scenario 4
True 0.427 0.604 0.673 0.688 0.686 0.707 0.697 0.715 0.744 0.804
PM 0.407 0.567 0.630 0.640 0.634 0.653 0.638 0.656 0.690 0.753
Difference (mean) 0.020 0.037 0.044 0.047 0.052 0.054 0.060 0.059 0.054 0.051
Difference (SD) 0.013 0.020 0.022 0.027 0.032 0.037 0.046 0.050 0.055 0.065
Scenario 5
True 0.450 0.645 0.704 0.709 0.705 0.723 0.712 0.725 0.754 0.812
PM 0.430 0.603 0.659 0.662 0.653 0.670 0.654 0.667 0.698 0.762
Difference (mean) 0.021 0.042 0.045 0.047 0.052 0.053 0.058 0.057 0.056 0.051
Difference (SD) 0.013 0.020 0.022 0.026 0.031 0.036 0.043 0.048 0.056 0.061
Scenario 6
True 0.412 0.579 0.657 0.679 0.683 0.705 0.697 0.713 0.744 0.803
PM 0.394 0.547 0.617 0.634 0.632 0.654 0.640 0.656 0.690 0.756
Difference (mean) 0.018 0.032 0.040 0.045 0.050 0.051 0.057 0.057 0.054 0.047
Difference (SD) 0.012 0.017 0.021 0.025 0.031 0.035 0.042 0.049 0.056 0.063
Scenario 7
True 0.297 0.487 0.612 0.657 0.671 0.702 0.697 0.715 0.744 0.807
PM 0.284 0.465 0.579 0.614 0.620 0.648 0.637 0.655 0.688 0.756
Difference (mean) 0.013 0.021 0.034 0.043 0.051 0.055 0.060 0.060 0.056 0.051
Difference (SD) 0.009 0.014 0.020 0.025 0.031 0.036 0.044 0.050 0.053 0.061
The BS values for Scenarios 4-6 are larger than those for Scenarios 1-3. This
is because the individual deviations of biomarker trajectories in Scenarios 4-6 have
smaller variance, leading to larger between-latent class variance relative to within-
latent class variance. We also note that when the individual intercepts and slopes are
negatively correlated, the BS values are larger compared to scenarios with indepen-
dent or positively correlated intercepts and slopes. Moreover, a larger measurement
error (Scenario 7) leads to poorer BS values when available biomarker information
is insufficient, especially when making prediction with no more than four repeated
51
biomarker observations. However, this influence is reduced when more biomarker ob-
servations are available.
Table 3.4 lists the mean PARs from “true” joint modeling, mean from of pattern
mixture model, and their mean differences and standard deviation. From Table 3.4
we detect the loss of PAR of pattern mixture model compared with the “true” mode.
Similar to the BS, compared with the standard deviation, these PAR losses are not
significantly away from 0. Moreover, compared with the size of PAR of the “true”
model, the pattern mixture model losses approximate 5% of the PAR.
We can find the same pattern of PAR loss in various scenarios as of BS loss. Among
various scenarios, Scenario 4-6 show larger PARs, compared with Scenario 1-3. When
the individual intercept and slope are negatively correlated, the PAR achieves larger
values compared with scenarios having independent or positively correlated intercepts
and slopes. Moreover, large measurement error (Scenario 7) do worsen PARs when
available biomarker information is insufficient, but this influence is diluted when more
than four biomarker observations are available. In contrast to the BS loss, the PAR
loss is easy to understand and interpret. For example, under Scenario 6 and at
prediction time 4, the pattern mixture model incorrectly predicts three out of 100
patients.
3.4.2 Simulation from Joint Model with Four Latent Classes
Now we assume the patients are from four latent classes of aGVHD. Compared
with Section 3.4.1, the number of latent classes is far smaller than the number of
patterns we choose in the pattern mixture model. Similar to Section 3.4.1, patients
in the same latent class share the same biomarker mean trajectory with individual
deviations, and same aGVHD probability, which follows a Weibull distribution. In
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Table 3.4: PAR of the pattern mixture model under simulation setting (1)
Predictionatweek 1 2 3 4 5 6 7 8 9 10
Scenario 1
True 0.505 0.638 0.693 0.705 0.704 0.724 0.718 0.732 0.762 0.816
PM 0.483 0.612 0.663 0.672 0.667 0.685 0.673 0.687 0.719 0.778
Difference (mean) 0.022 0.026 0.029 0.034 0.038 0.039 0.045 0.045 0.042 0.038
Difference (SD) 0.028 0.027 0.029 0.036 0.043 0.048 0.058 0.064 0.072 0.086
Scenario 2
True 0.543 0.691 0.738 0.745 0.743 0.759 0.748 0.761 0.783 0.838
PM 0.519 0.662 0.706 0.710 0.703 0.715 0.699 0.713 0.739 0.796
Difference (mean) 0.024 0.029 0.032 0.035 0.041 0.044 0.049 0.048 0.044 0.042
Difference (SD) 0.027 0.027 0.030 0.036 0.043 0.047 0.058 0.064 0.070 0.081
Scenario 3
True 0.483 0.617 0.680 0.701 0.708 0.732 0.723 0.742 0.772 0.828
PM 0.460 0.590 0.649 0.666 0.667 0.688 0.674 0.694 0.727 0.790
Difference (mean) 0.022 0.027 0.031 0.035 0.041 0.044 0.049 0.048 0.045 0.038
Difference (SD) 0.028 0.028 0.029 0.036 0.042 0.048 0.060 0.066 0.072 0.083
Scenario 4
True 0.557 0.730 0.789 0.802 0.803 0.817 0.811 0.824 0.843 0.884
PM 0.534 0.700 0.754 0.764 0.763 0.775 0.765 0.778 0.802 0.848
Difference (mean) 0.023 0.031 0.035 0.037 0.040 0.043 0.047 0.045 0.041 0.036
Difference (SD) 0.027 0.027 0.028 0.033 0.036 0.042 0.051 0.055 0.060 0.067
Scenario 5
True 0.582 0.769 0.816 0.821 0.821 0.832 0.825 0.834 0.853 0.890
PM 0.559 0.738 0.784 0.787 0.784 0.792 0.782 0.791 0.812 0.860
Difference (mean) 0.023 0.031 0.033 0.035 0.037 0.040 0.043 0.042 0.040 0.030
Difference (SD) 0.026 0.025 0.026 0.03 0.033 0.039 0.046 0.051 0.060 0.059
Scenario 6
True 0.538 0.708 0.774 0.794 0.800 0.815 0.811 0.823 0.843 0.882
PM 0.517 0.679 0.743 0.758 0.761 0.774 0.767 0.778 0.802 0.853
Difference (mean) 0.021 0.028 0.031 0.036 0.039 0.041 0.045 0.045 0.041 0.029
Difference (SD) 0.027 0.025 0.027 0.031 0.035 0.038 0.047 0.051 0.059 0.061
Scenario 7
True 0.399 0.613 0.733 0.775 0.790 0.814 0.811 0.824 0.843 0.885
PM 0.381 0.591 0.703 0.739 0.750 0.770 0.765 0.778 0.803 0.854
Difference (mean) 0.017 0.022 0.030 0.036 0.040 0.044 0.047 0.046 0.040 0.031
Difference (SD) 0.029 0.027 0.028 0.031 0.037 0.042 0.051 0.057 0.060 0.065
contrast to Section 3.4.1, in Setting (2) patients in the same latent class share a more
widespread distribution of time-to-aGVHD, so the variation of prediction increases.
The details of simulation parameters can be found in Table 3.5.
As in Section 3.4.1, we calculate the means BS and PAR values from the pattern
mixture model and its theoretically best counterpart, together with the difference be-
tween the two. The BSs and PARs are shown in Table 3.6 and Table 3.7 respectively.
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Table 3.5: Simulation parameters for joint modeling with four latent classes
Latent
Class
Population
Proportion
Time to aGVHD (Weibull) Biomarker Trajectory
λ κ Intercept Slope
1 20% 11.256 22 10 1
2 20% 8.91 14 10 4
3 30% 5.89 10 10 7
4 30% 2.715 5 10 9
The results list in Table 3.6 show a pattern similar to that in Table 3.3. There
are consistent losses of BSs from the pattern mixture model, compared with BSs
from a “true” model. However, these differences are not significantly different from
0. When we compare the BSs across various scenarios, we also find the same pattern
as in Table 3.3. Scenario 4-6 show larger BSs, compared with scenario 1-3. When
the individual intercepts and slopes are negatively correlated, the BS achieves larger
values compared with scenarios having independent or positively correlated intercepts
and slopes. Moreover, large measurement errors lower BSs when available biomarker
information is insufficient, especially when making prediction with no more than four
repeated biomarker observations.
In contrast to Table 3.3, the BS values in Table 3.6 are relatively smaller. This
is because the data simulated from a joint model with four latent classes has wider
distribution of times-to-aGVHD, leading to larger variation in prediction, and thus
smaller BS values.
Based on Table 3.7, PARs show similar pattern as in Table 3.4, with a reduction
in their corresponding values. The maximum PAR we can theoretically achieve is
around 60%, which means we can only accurately predict the times-to-aGVHD for
60 out of 100 patients. In this case, it would be helpful if we can widen the window
of accuracy of PARs, including predictions that are one week earlier or later than the
exact time-to-aGVHD.
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Table 3.6: Brier Score of the pattern mixture model under simulation setting (2)
Predictionatweek 1 2 3 4 5 6 7 8 9 10
Scenario 1
True 0.317 0.389 0.380 0.360 0.406 0.452 0.384 0.441 0.529 0.517
PM 0.299 0.364 0.352 0.330 0.375 0.420 0.345 0.403 0.498 0.482
Difference (mean) 0.018 0.025 0.029 0.031 0.031 0.032 0.039 0.038 0.031 0.035
Difference (SD) 0.013 0.015 0.018 0.020 0.022 0.023 0.030 0.034 0.034 0.048
Scenario 2
True 0.346 0.417 0.405 0.377 0.424 0.474 0.396 0.455 0.547 0.516
PM 0.324 0.389 0.373 0.344 0.391 0.440 0.355 0.414 0.515 0.480
Difference (mean) 0.022 0.028 0.031 0.033 0.034 0.034 0.042 0.041 0.032 0.036
Difference (SD) 0.014 0.016 0.019 0.021 0.022 0.026 0.033 0.037 0.034 0.049
Scenario 3
True 0.308 0.389 0.387 0.368 0.416 0.468 0.392 0.451 0.544 0.518
PM 0.295 0.368 0.360 0.338 0.385 0.437 0.353 0.413 0.514 0.484
Difference (mean) 0.014 0.021 0.027 0.030 0.031 0.031 0.040 0.038 0.030 0.034
Difference (SD) 0.013 0.015 0.017 0.019 0.021 0.023 0.030 0.033 0.034 0.049
Scenario 4
True 0.361 0.441 0.432 0.398 0.448 0.501 0.414 0.474 0.571 0.519
PM 0.341 0.413 0.401 0.364 0.413 0.467 0.371 0.431 0.542 0.484
Difference (mean) 0.020 0.028 0.031 0.034 0.035 0.034 0.043 0.043 0.029 0.035
Difference (SD) 0.014 0.016 0.019 0.021 0.023 0.026 0.033 0.037 0.033 0.047
Scenario 5
True 0.381 0.453 0.439 0.402 0.451 0.509 0.418 0.477 0.576 0.519
PM 0.357 0.422 0.406 0.366 0.415 0.472 0.372 0.433 0.549 0.488
Difference (mean) 0.024 0.031 0.033 0.036 0.036 0.036 0.046 0.044 0.026 0.032
Difference (SD) 0.014 0.017 0.020 0.022 0.024 0.026 0.033 0.038 0.033 0.045
Scenario 6
True 0.349 0.437 0.431 0.399 0.449 0.506 0.416 0.477 0.574 0.520
PM 0.332 0.411 0.402 0.366 0.415 0.472 0.372 0.435 0.545 0.483
Difference (mean) 0.017 0.026 0.029 0.033 0.035 0.034 0.044 0.042 0.029 0.036
Difference (SD) 0.014 0.016 0.019 0.021 0.024 0.026 0.032 0.038 0.034 0.050
Scenario 7
True 0.293 0.419 0.425 0.396 0.446 0.502 0.413 0.473 0.572 0.518
PM 0.276 0.394 0.396 0.364 0.413 0.468 0.370 0.432 0.543 0.484
Difference (mean) 0.017 0.025 0.029 0.032 0.034 0.034 0.043 0.042 0.029 0.034
Difference (SD) 0.011 0.015 0.019 0.021 0.024 0.026 0.033 0.037 0.035 0.049
3.4.3 Joint Model with Shared Random Effects and Four Latent Classes
Same as JMLC, another counterpart of the pattern mixture model, JMSR also
links longitudinal data to a primary event. However, JMSR assumes the patients have
the same pattern of biomarker trajectories over time, and their times-to-aGVHD de-
pend on only the individual deviation of biomarkers from the global mean. Here we
generalize the assumption of both JMLC and JMSR, assuming that patients are in-
herent of various risk groups of aGVHD, and their times-to-aGVHD depend on both
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Table 3.7: PAR of the pattern mixture model under simulation setting (2)
Predictionatweek 1 2 3 4 5 6 7 8 9 10
Scenario 1
True 0.459 0.520 0.503 0.485 0.521 0.557 0.496 0.541 0.618 0.590
PM 0.436 0.492 0.468 0.448 0.481 0.520 0.451 0.497 0.584 0.546
Difference (mean) 0.022 0.028 0.035 0.038 0.040 0.037 0.045 0.045 0.034 0.044
Difference (SD) 0.028 0.030 0.037 0.042 0.044 0.047 0.059 0.062 0.065 0.090
Scenario 2
True 0.487 0.545 0.523 0.499 0.535 0.573 0.505 0.551 0.629 0.585
PM 0.461 0.515 0.487 0.459 0.495 0.534 0.457 0.503 0.595 0.543
Difference (mean) 0.026 0.030 0.036 0.040 0.041 0.039 0.048 0.048 0.033 0.043
Difference (SD) 0.029 0.031 0.038 0.042 0.043 0.049 0.061 0.065 0.064 0.086
Scenario 3
True 0.450 0.521 0.508 0.491 0.529 0.570 0.503 0.550 0.631 0.592
PM 0.432 0.495 0.475 0.454 0.491 0.532 0.456 0.504 0.597 0.547
Difference (mean) 0.018 0.025 0.033 0.037 0.038 0.038 0.047 0.046 0.034 0.045
Difference (SD) 0.028 0.030 0.038 0.041 0.043 0.050 0.060 0.064 0.068 0.094
Scenario 4
True 0.502 0.567 0.547 0.519 0.557 0.596 0.522 0.569 0.650 0.591
PM 0.479 0.539 0.513 0.483 0.519 0.561 0.477 0.525 0.618 0.547
Difference (mean) 0.023 0.028 0.034 0.037 0.038 0.035 0.044 0.043 0.032 0.044
Difference (SD) 0.028 0.030 0.037 0.040 0.042 0.047 0.058 0.062 0.066 0.094
Scenario 5
True 0.520 0.576 0.552 0.522 0.559 0.602 0.525 0.571 0.654 0.593
PM 0.493 0.547 0.519 0.484 0.521 0.565 0.478 0.527 0.624 0.551
Difference (mean) 0.027 0.029 0.034 0.037 0.038 0.037 0.047 0.044 0.029 0.042
Difference (SD) 0.028 0.030 0.036 0.039 0.041 0.046 0.057 0.060 0.061 0.086
Scenario 6
True 0.491 0.563 0.547 0.520 0.558 0.601 0.524 0.572 0.653 0.593
PM 0.470 0.536 0.514 0.483 0.519 0.564 0.478 0.527 0.620 0.546
Difference (mean) 0.021 0.027 0.033 0.036 0.039 0.036 0.047 0.044 0.033 0.047
Difference (SD) 0.028 0.031 0.037 0.041 0.043 0.047 0.058 0.063 0.064 0.090
Scenario 7
True 0.431 0.546 0.541 0.516 0.555 0.595 0.519 0.566 0.650 0.589
PM 0.412 0.520 0.508 0.480 0.516 0.559 0.473 0.523 0.619 0.546
Difference (mean) 0.020 0.026 0.033 0.036 0.039 0.036 0.046 0.043 0.031 0.043
Difference (SD) 0.027 0.030 0.039 0.042 0.044 0.048 0.060 0.063 0.067 0.093
the risk group and their individual deviations of biomarker trajectory.
In this setting, the biomarker observations Yi and time-to-aGVHD Ti are assumed
independent conditioning on random effects bi, which follow a mixture of multivariate
normal distribution. Recently there are some researchers trying to extend joint model-
ing to incorporate mixture distribution of shared random effect with simplified binary
outcomes. Given the increasing numbers of parameters, and the booming difficulty
in constructing the likelihood, these researchers adopted the Bayesian framework to
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achieve posterior predictive distribution on outcomes (Jiang et al., 2015). This ap-
proach can thoroughly remove bias, but it is computationally intense.
Here, we use the pattern mixture model to avoid the technique difficulties raised
by shared random effects of mixture distributions. Its performance is evaluated by
comparing the prediction with the ideal counterpart when all the parameters are
known ahead. Similar to Equation 3.6, the “true” probability of aGVHD under
setting (3) can be approximated by the following:
Pr(k + l ≤ Tm ≤ k + l + 1|Ti ≥ k,Y m,θ)
=
∫
Pr(k + l ≤ Tm ≤ k + l + 1|Ti ≥ k,Y m, bm,θ)Pr(bm|Tm ≥ k,Y m,θ)dbm
≈
G∑
g=1
Pr(Tm ∈ (k + l, k + l + 1)|Tm > k, bm(g),θ)Pr(Tm ≥ k|bm(g),θ)Pr(Y i|bm(g), θ)Pr(bm(g)|θ)
G
∫
Pr(Tm ≥ k|bm,θ)Pr(Y m|bm,θ)Pr(bm|θ)dbm
=
∑G
g=1 Pr(k + l ≤ Tm ≤ k + l + 1|bm(g),θ)Pr(Y m|bm(g), θ)Pr(bm(g)|θ)∑G
g=1 Pr(Tm ≥ k|bm(g),θ)Pr(Y m|bm(g), θ)Pr(bm(g)|θ)
(3.7)
where θ is the simulation parameters, and Y m is the biomarker observations of sub-
ject m. Here bm follows a mixture normal distribution with J components, and J
is the number of latent classes. Since there is no closed form for calculating the in-
tegral in Equation 3.7, we simulate G sets of random effects from their distribution
Pr(bm|θ), and average their effects to approximate this integral.
We apply the same simulation parameters as in setting (2), Table 3.5. The BSs and
PARs are stored in Table 3.8 and Table 3.9 respectively. Similar to Table 3.3 and Table
3.6, the mean losses of BS in setting (3) are not significantly away from 0. However,
the mean losses of BS in setting (3) are smaller than mean losses of corresponding
BS in setting (1) and (2). This is because when data are simulated from setting (3),
biomarker trajectories and times-to-aGVHD share both the latent class and random
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Table 3.8: Brier Score of the pattern mixture model under simulation setting (3)
Prediction at week 1 2 3 4 5 6 7 8 9 10
Scenario 1
E(BSJM) 0.317 0.433 0.494 0.505 0.534 0.549 0.548 0.586 0.607 0.713
E(BSPM) 0.320 0.423 0.472 0.476 0.501 0.513 0.509 0.549 0.568 0.676
E(BSJM −BSPM) -0.003 0.011 0.022 0.030 0.034 0.036 0.039 0.038 0.039 0.038
SD(BSJM −BSPM) 0.018 0.019 0.020 0.022 0.025 0.028 0.033 0.037 0.044 0.053
Scenario 2
E(BSJM) 0.314 0.429 0.493 0.503 0.531 0.546 0.545 0.582 0.601 0.713
E(BSPM) 0.318 0.417 0.468 0.472 0.495 0.508 0.504 0.543 0.561 0.675
E(BSJM −BSPM) -0.004 0.012 0.025 0.032 0.036 0.038 0.041 0.039 0.040 0.038
SD(BSJM −BSPM) 0.019 0.020 0.021 0.024 0.026 0.029 0.034 0.038 0.045 0.055
Scenario 3
E(BSJM) 0.327 0.436 0.491 0.502 0.529 0.545 0.545 0.580 0.600 0.709
E(BSPM) 0.327 0.424 0.469 0.473 0.496 0.508 0.507 0.542 0.563 0.673
E(BSJM −BSPM) 0.000 0.012 0.022 0.029 0.033 0.036 0.038 0.038 0.038 0.035
SD(BSJM −BSPM) 0.018 0.020 0.022 0.024 0.025 0.029 0.033 0.037 0.043 0.049
Scenario 4
E(BSJM) 0.329 0.433 0.498 0.492 0.529 0.541 0.526 0.581 0.568 0.691
E(BSPM) 0.329 0.420 0.475 0.461 0.494 0.504 0.483 0.540 0.523 0.644
E(BSJM −BSPM) 0.000 0.013 0.023 0.031 0.035 0.037 0.043 0.040 0.045 0.046
SD(BSJM −BSPM) 0.017 0.019 0.019 0.022 0.025 0.028 0.034 0.038 0.046 0.058
Scenario 5
E(BSJM) 0.330 0.428 0.497 0.491 0.528 0.541 0.525 0.578 0.568 0.691
E(BSPM) 0.329 0.415 0.469 0.456 0.488 0.498 0.477 0.532 0.521 0.645
E(BSJM −BSPM) 0.002 0.013 0.028 0.036 0.040 0.043 0.047 0.046 0.047 0.046
SD(BSJM −BSPM) 0.018 0.019 0.019 0.022 0.025 0.029 0.035 0.038 0.046 0.060
Scenario 6
E(BSJM) 0.337 0.439 0.499 0.491 0.528 0.540 0.525 0.579 0.569 0.690
E(BSPM) 0.335 0.425 0.475 0.460 0.493 0.502 0.481 0.536 0.526 0.647
E(BSJM −BSPM) 0.002 0.015 0.023 0.031 0.035 0.038 0.044 0.043 0.044 0.043
SD(BSJM −BSPM) 0.018 0.019 0.020 0.023 0.025 0.030 0.034 0.038 0.044 0.057
Scenario 7
E(BSJM) 0.256 0.382 0.467 0.473 0.518 0.535 0.521 0.578 0.569 0.692
E(BSPM) 0.246 0.366 0.445 0.442 0.484 0.499 0.478 0.537 0.522 0.644
E(BSJM −BSPM) 0.010 0.016 0.022 0.031 0.034 0.037 0.043 0.041 0.047 0.048
SD(BSJM −BSPM) 0.013 0.017 0.018 0.021 0.023 0.027 0.033 0.037 0.048 0.060
effects, leading to a stronger connection between the repeated biomarkers and times-
to-aGVHD. The stronger the connection is, the relatively better the pattern mixture
model performs. When comparing among various scenarios, we find the same pattern
of BSs as in previous two settings.
The mean losses of PAR in setting (3) are not significantly away from 0, and they
are smaller than mean losses of corresponding PAR in setting (1) and (2), same as
BS. When comparing among various scenarios, we found the same pattern of PARs
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Table 3.9: PAR of the pattern mixture model under simulation setting (3)
Predictionatweek 1 2 3 4 5 6 7 8 9 10
Scenario 1
E(PARJM) 0.417 0.551 0.610 0.623 0.647 0.661 0.659 0.690 0.704 0.786
E(PARPM) 0.426 0.541 0.591 0.595 0.617 0.628 0.625 0.658 0.671 0.760
E(PARJM − PARPM) -0.009 0.010 0.019 0.028 0.030 0.033 0.034 0.033 0.033 0.027
SD(PARJM − PARPM) 0.037 0.035 0.032 0.036 0.038 0.042 0.049 0.052 0.062 0.068
Scenario 2
E(PARJM) 0.417 0.548 0.610 0.620 0.643 0.656 0.655 0.684 0.697 0.785
E(PARPM) 0.427 0.539 0.589 0.593 0.614 0.624 0.621 0.654 0.666 0.762
E(PARJM − PARPM) -0.010 0.009 0.021 0.027 0.030 0.032 0.034 0.031 0.031 0.023
SD(PARJM − PARPM) 0.039 0.033 0.032 0.037 0.040 0.044 0.050 0.053 0.065 0.070
Scenario 3
E(PARJM) 0.430 0.553 0.606 0.618 0.641 0.654 0.654 0.683 0.698 0.785
E(PARPM) 0.436 0.543 0.587 0.593 0.614 0.625 0.624 0.654 0.668 0.759
E(PARJM − PARPM) -0.006 0.010 0.019 0.025 0.027 0.029 0.030 0.028 0.030 0.026
SD(PARJM − PARPM) 0.037 0.034 0.034 0.036 0.037 0.042 0.049 0.052 0.064 0.065
Scenario 4
E(PARJM) 0.439 0.552 0.614 0.611 0.642 0.653 0.640 0.686 0.672 0.768
E(PARPM) 0.441 0.541 0.594 0.583 0.610 0.620 0.601 0.652 0.633 0.732
E(PARJM − PARPM) -0.001 0.011 0.019 0.028 0.033 0.033 0.039 0.034 0.039 0.036
SD(PARJM − PARPM) 0.037 0.034 0.032 0.035 0.040 0.045 0.052 0.051 0.066 0.078
Scenario 5
E(PARJM) 0.442 0.547 0.613 0.609 0.640 0.652 0.638 0.682 0.672 0.769
E(PARPM) 0.444 0.540 0.594 0.582 0.609 0.619 0.599 0.648 0.630 0.734
E(PARJM − PARPM) -0.002 0.007 0.019 0.027 0.031 0.032 0.040 0.034 0.042 0.035
SD(PARJM − PARPM) 0.038 0.033 0.031 0.036 0.039 0.043 0.050 0.052 0.067 0.077
Scenario 6
E(PARJM) 0.450 0.556 0.614 0.609 0.639 0.650 0.636 0.682 0.671 0.765
E(PARPM) 0.450 0.547 0.596 0.585 0.611 0.620 0.600 0.649 0.634 0.733
E(PARJM − PARPM) 0.000 0.010 0.018 0.024 0.028 0.030 0.036 0.033 0.037 0.032
SD(PARJM − PARPM) 0.036 0.033 0.032 0.035 0.038 0.043 0.052 0.052 0.066 0.074
Scenario 7
E(PARJM) 0.358 0.496 0.583 0.590 0.631 0.648 0.636 0.684 0.674 0.771
E(PARPM) 0.339 0.477 0.562 0.564 0.601 0.615 0.598 0.651 0.634 0.735
E(PARJM − PARPM) 0.019 0.019 0.021 0.027 0.030 0.033 0.038 0.033 0.041 0.037
SD(PARJM − PARPM) 0.034 0.035 0.032 0.036 0.038 0.044 0.050 0.055 0.070 0.080
as in previous two settings.
3.5 Discussion
In this chapter, we introduce the pattern mixture model to make dynamic pre-
dictions of time-to-aGVDH with repeated biomarkers. The pattern mixture model
identifies the patterns, or in other words, the latent classes of aGVHD, based on
solely the times-to-aGVHD, and then summarizes the features of repeated biomark-
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ers within each pattern. Our simulation study has shown that, when the patients’
repeated biomarkers are strongly correlated with their times-to-aGVHD, pattern mix-
ture model perform reasonably good.
We examine how the pattern mixture model performs when patients are of vari-
ous risk classes of aGVHD. We consider two settings: there are inherent eleven latent
classes, or four latent classes, as discussed in Chapter II. When patients are from
eleven latent classes, their times-to-aGVHD are highly correlated with the repeated
biomarker process. Under this setting, the pattern mixture model introduces a small
loss to the accuracy of the time-to-aGVHD prediction, and approximately 3 out of
100 patients will be miss-predicted of their time-to-aGVHD. When patients are from
four latent classes of aGVHD, the BS and PAR of the pattern mixture model de-
crease. However, it shows a stable loss of prediction accuracy as in setting (1).
In a more sophisticated setting, we assume the time-to-aGVHD not only depends
on the latent class membership, but also on the individual deviations of biomarker
trajectories. In this case, the pattern mixture model performs consistently good, even
better than that in setting (2). This is because the shared random effects reinforce
the correlation between biomarkers and the time-to-aGVHD, making the time-to-
aGVHD itself as a stronger indicator of aGVHD latent class.
We also find that the overall prediction is better when the biomarker trajec-
tories of patients between groups are more distinguishable with small variance of
random effects. Moreover, larger measurement errors worsen prediction when avail-
able biomarker information is insufficient, but this influence is diluted when more
biomarkers are collected. We also observe that when the random effects are negative
correlated, the prediction improves.
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Therefore, we conclude that the pattern mixture model can be applied to the
dataset including both longitudinal biomarkers and times-to-aGVHD. It introduces
small loss of prediction accuracy but it is more flexible and convenient to execute.
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CHAPTER IV
Generalized Pattern Mixture Model in the
Prediction of Time-to-Event
4.1 Introduction
Biomarkers have been applied in medical practice to accelerate disease diagno-
sis, monitor patients’ health conditions, and predict treatment effects (Naylor, 2003;
Mayeux, 2004). Many recent studies have demonstrated that biomarker profiles differ
by person, and this difference cannot be fully explained by individual-level random ef-
fects only. For example, Proust-Lima et al. (2016) found that there are four subgroups
of dementia patients, and each group has a distinct pattern of how the semantic mem-
ory changes over time.
Each risk group might have different risks of adverse events, and thus the length of
follow-up also differs by risk group. In this case, identifying the risk group is impor-
tant; otherwise, the population from the low risk group will be over-represented given
the fact that they have more biomarker observations. In Chapter III, we introduced
how to apply the pattern mixture model to identify different biomarker trajectories
in patients who have received BMT. Patients’ risk group membership was determined
by their times-to-aGVHD. Patients in the same risk group had an equal number of
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biomarker observations, and we made the assumption that they shared the same
biomarkers distribution.
In Chapter III, patients’ times-to-aGVHD were grouped in weeks, and we as-
sumed patients who had developed aGVHD in the same week after BMT shared
similar biomarker patterns. This setting can be generalized to other diseases. In
practice, patients’ onset of non-fatal disease might not be accurately recorded, espe-
cially when the disease is self-reported. Another example is the follow-up of patients
with chronic diseases, whether a patient’s time-to-event is recorded promptly depends
on the timing and frequency of follow-up after hospital discharge. In these cases, it is
reasonable to group the patients’ times-to-event into discrete intervals. In practice,
these time intervals might or might not be of equal length. For example, in a study
of the elderly at risk for dementia, the biomarkers (semantic memory scores) were
measured at baseline, year 1, 3, 5, 8, 10, and so forth (Proust-Lima et al., 2016).
In Chapter III, we showed how to use the pattern mixture model to a setting,
in which patients were either free of aGVHD or their onset of aGVHD was com-
pletely recorded. Patients receiving BMT are under close monitoring. Moreover,
aGVHD is a complication typically happening within 100 days after BMT. In this
case, we do not have missing observations in patients’ times-to-aGVHD or biomarker
observations. However, in other clinical studies, the event time might not be fully
observed due to administrative censoring, loss to follow up, or competing risks. For
chronic diseases, it might take years to observe the progression of a disease or death,
so that the missingness of event times is quite common. The censored participants
still contribute to the analysis by the partial information that they are event-free at
the time of censoring. Classic methods, such as parametric survival regression and
semi-parametric Cox regression, utilize this partial information and achieve larger
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power compared with the complete-case method. Moreover, when the event time is
not missing completely at random, complete cases are a biased sample of the orig-
inal dataset. Thus, the complete case analysis generates biased parameter estimation.
There is another type of missingness in event times, when the patients are “cured.”
For example, Rama et al. (2010) found that if patients with locally advanced breast
cancer survived seven years after their cancer diagnosis, they were considered to be
cured and would be less likely to die from breast cancer. Dal Maso et al. (2014) found
that among patients with thyroid, testis or corpus uteri cancer, the cured fraction was
as high as 90%. These cured patients might share different clinical characteristics than
susceptible patients; thus, it is important to identify the cured patients and model
their biomarker patterns separately.
In this chapter, we will discuss how to generalize this pattern mixture model in the
prediction of time-to-event, considering both the cured fraction of the population and
random censoring in the event time. The key improvement in this project is that we
utilize the information from the censored patients, estimate their probability of being
cured, and refine the parameter estimation in the longitudinal biomarker process for
both cured and susceptible patients.
The rest of this chapter is organized as follows. First, we will introduce how
to structure the model and make predictions with the generalized pattern mixture
model (GPMM). Second, we simulate data with independent and dependent censor-
ing, and evaluate the performance of this GPMM compared to the complete-case
pattern mixture model. We conclude the chapter with a discussion.
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4.2 Methods
Similar to Chapter III, we define Ti to be the recorded last follow-up in weeks
for subject i, which is the minimum of time-to-event in weeks for subject i, T ∗i , or
the censoring time Si. We also define δi as the indicator of whether subject i has
experienced aGVHD (δi = 1) or has been censored (δi = 0).
We define hi as the group indicator of participant i, and hi = T
∗
i if the patient
develops aGVHD T ∗i weeks after BMT. Given there are fewer patients who develop
aGVHD after 80 days, we combine all the aGVHD cases ten weeks after BMT and
define that they all belong to group 10. The “cured” patients, who will never develop
aGVHD after BMT, will join group 11. Unlike the aGVHD data in Chapter III, hi is
partially observed because T ∗i is only partially observed. We cannot tell whether an
early censored patient is aGVHD-free or will develop aGVHD later.
We also define Yi = (Yi(t1), Yi(t2), · · · , Yi(tni)) as the biomarker history of subject
i at time (t1, t2, · · · , tni), where ni is the total number of biomarker observations for
subject i, for i = 1, 2, · · · , n. For simplicity, we assume that the continuous biomarker
observations Yi change linearly over time, but it is straightforward to generalize them
as other functional forms of time. Random effects bi = (b0i, b1i) are introduced to
reflect the individual deviation of the biomarker trajectory from the population mean,
where bi follows a Gaussian distribution with mean 0 and variance-covariance D.
We assume the mean biomarker trajectory depends on the patient’s time-to-
aGVHD. The susceptible patients are naturally grouped by their times-to-aGVHD
week until day 100 after BMT. Patients experiencing aGVHD within the same week
share the same biomarker pattern, therefore aGVHD-free patients in group 11 will
share a distinct biomarker pattern than those susceptible patients.
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Let Bi = (Yi, Ti, δi) represent the observed data for subject i, and Oi = (Yi, hi)
denote the complete data, in which hi are not fully observed.
We assume the biomarker observations, Yi, follow a Gaussian distribution such
that:
Yi|hi = h = Xiβ(h) +Zibi + i (4.1)
Yi(tj)|hi = h = β(h)0 + β(h)1 tj + b0i + b1itj + i(tj) (4.2)
where Xi and Zi is the design matrix for subject i, and the measurement error i
follows a Gaussian distribution with mean 0 and variance σ2Ini . Patients in each
risk group h share the same mean profile of biomarker, denoting by group-specific
parameters β(h).
Define ph as the marginal probability of a patient coming from group h, specif-
ically, the patient has experienced aGVHD after the hth week, or this patient is
aGVHD-free if h = 11.
Let θ = (β = (β(1),β(2), · · · ,β(11)), D, σ2) denote the parameters involved in the
longitudinal biomarker process, and ξ = (θ,pi = (p1, p2, · · · , p11)) be the complete
parameter set. The likelihood function given the complete data O = (Y i, hi) is:
L(ξ|O) =
n∏
i=1
11∏
h=1
[phf(Yi|β(h), D, σ2)]I(hi=h)
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The corresponding log-likelihood function is:
l(ξ|O) =
n∑
i=1
11∑
h=1
[I(hi = h)log(ph) + I(hi = h)log(f(Yi|β(h), D, σ2))]
= l1(ph|O) + l2(θ|O) (4.3)
where l1(ph|O) =
n∑
i=1
11∑
h=1
I(hi = h)log(ph) involving only the marginal probability of
latent classes, and l2(θ|O) =
n∑
i=1
11∑
h=1
I(hi = h)log(f(Yi|β(h), D, σ2)) involving only the
biomarker distribution. Thus, the log-likelihood function in Equation 4.3 is separated
into two parts involving parameter ph and θ respectively. Given the complete data O,
it would be straightforward to achieve the MLE of ξ; however, with only the observed
data B, we cannot construct the likelihood function in a closed form. One solution
is using the Expectation-Maximization (EM) algorithm to facilitate the parameter
estimation process.
4.2.1 Model fitting
The EM algorithm starts with computing the expectation of unobserved data, and
maximize the likelihood function given these expectations. In our setting, patients’
true time-to-aGVHD T ∗i , or equivalent group indicator hi, are only partially observed,
so we will begin with obtaining the expectation of unobserved hi.
For an observed cured patient, the group indicator hi is 11; and hi = T
∗
i for a
patient who had experienced an event. For a censored patient, we need to calculate
the expected group membership hi. Given the log-likelihood in Equation 4.3, at the
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q + 1 step, the expectation of hi is:
E(hi) =

11, T ∗i =∞
T ∗i , δi = 1
p
(q)
h f(Yi|β(h)(q), D(q), σ2(q))∑11
h=c p
(q)
h f(Yi|β(h)(q), D(q), σ2(q))
, δi = 0, Ti = c
(4.4)
For censored patients, the expectation of group indicator hi equals the weighted
probability of being in group h given the patient’s follow-up time and biomarker
observations. Thus, the estimated probability of patient i’s group membership, pi =
(p1i, p2i, · · · , p11,i), could be calculated as:
pi =

(0, · · · , 1), T ∗i =∞
(0, · · · , 0, pci = 1, 0, · · · 0, ), δi = 1, Ti = c
(0, · · · , 0, pci = p
(q)
h f(Yi|β(h)(q), D(q), σ2(q))∑11
h=c p
(q)
h f(Yi|β(h)(q), D(q), σ2(q))
, · · · ), δi = 0, Ti = c
To facilitate the parameter estimation in the biomarker process, we obtain the
expectation of unobserved random effects bi and measure errors i as in Chapter
2.2.2. DefineH(q) = ZiD
(q)Z ′i+σ
2(q)Ini , and given the joint distribution of (Yi, bi, i)
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we obtain:
E(bib
′
i|Yi, ξ(q)) = Ebi|Yi(bi|Yi)Ebi|Yi(bi|Yi)
′ + covbi|Yi(bi|Yi)
E(eie
′
i|Yi, ξ(q)) = Eei|Yi(ei|Yi)Eei|Yi(ei|Yi)
′ + tr{covei|Yi(ei|Yi)}
where Ebi|Yi(bi|Yi, hi = h) = D
(q)ZiH
(q)−1(Yi −Xiβ(h))
covbi|Yi(bi|Yi, hi = h) = D
(q) −D(q)ZiH(q)−1ZiD(s)
Eei|Yi(ei|Yi, hi = h) = σ
2(q)H(q)
−1
(Yi −Xiβ(h))
covei|Yi(bi|Yi, hi = h) = σ
2(q)(Ini − σ2H(q)−1)
With the complete data sufficient statistics (hi, bib
′
i, eie
′
i), we can compute the
expectation of log-likelihood l1(ph|O) and l2(θ|O). In the q + 1 iteration and the M-
step, we can achieve the MLE for parameters ξ(q+1) = (p
(q+1)
h ,θ
(q+1)) by maximizing
the corresponding expectation of log-likelihood. The MLE of ph is:
p̂h =
1
n
n∑
i=1
phi (4.5)
The MLEs of parameters in longitudinal biomarker process, θ(q+1), are:
D̂ =
1
n
n∑
i=1
[ 11∑
h=1
phiE(bi|Yi, hi = h)E(bi|Yi, hi = h)′ + covbi|Yi(bi|Yi)
]
σ̂2 =
1∑n
i=1 ni
n∑
i=1
[ 11∑
h=1
phiE(ei|Yi, hi = h)E(ei|Yi, hi = h)′ + tr{covei|Yi(ei|Yi)}
]
β̂
(h)
=
[ n∑
i=1
phiX
′
iĤi
−1Xi
]−1[ n∑
i=1
phiX
′
iĤi
−1Yi
]
(4.6)
We repeat the above E-step and M-step until we reach some pre-specified conver-
gence criteria. Finally, we obtain the parameter estimations for the marginal cure
probability ph and the biomarker trajectories θ. With these parameter estimations,
we could predict one patient’s risk of events given his/her current available biomarker
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records.
4.2.2 Prediction with Generalized Pattern Mixture Model
The marginal distribution of observed biomarkers is a finite mixture of Gaussian
distribution, and the posterior probability of a new patient m developing aGVHD at
week j, with the observed biomarkers history by week k Ym = (Ym1, Ym2, · · · , Ym,k),
is that:
Pr(Tm = j|Ym, ξ) = f(Ym|β
(j), D, σ2)Pr(hm = j)∑11
l=k f(Ym|β(l), D, σ2)P (hm = l)
(4.7)
for j ≥ k. Bayes’ theorem is applied here to compute the posterior probability of
subject m experiencing the event in week j given his/her biomarker history Ym.
4.3 Simulation and Result
In this section, we evaluate the benefit of adjusting for the cured fraction in the
pattern mixture model, compared with using only complete cases. We consider the
scenarios with independent and dependent censoring. In practice, independent cen-
soring is mainly caused by administrative censoring or random drop-out. Multiple
reasons contribute to dependent censoring, such as competing risks or other adverse
events. We compare the prediction performance between the generalized pattern mix-
ture model and pattern mixture model with complete cases only in these two scenarios.
Data are simulated from a pattern mixture distribution with 11 patterns, repre-
senting time-to-event after week 1, week 2, · · · , week 10, and the “cured” patients.
Patients in each pattern share a distinct mean biomarker profile with individual-
specified random effects. For the sake of simplicity, we assume the mean biomarker
trajectory is a linear function of time. The independent censoring time is simulated
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from a uniform (1.5,17), resulting in around 34% censoring. In the dependent censor-
ing scenario, the censoring time is simulated from a uniform distribution range from
1.5 to 15 plus the true event time. So the probability of censoring depends on the
true event time. This results in around 35% censoring.
In each simulation, a sample of 220 patients is generated as the training set, with
their follow-up of biomarkers truncated by their longest follow-up time, the true time-
to-event or censoring, whichever comes first. Another dataset of 220 patients is also
generated from the same distribution and used as a test set. One thousand simu-
lations are executed to evaluate the performance of the generalized pattern mixture
model against complete-case pattern mixture model.
Similar to Chapter III, we use a dynamic Brier Score to summarize the perfor-
mance of prediction. As a reminder, we define the dynamic BS as:
BS(k) = 1− 1∑n
i=1 I(Ti ≥ k)
n∑
i=1
J∑
j=1
I(Ti ≥ k)[fij(Yi)− oij]2 (4.8)
where oij = 1 if patient i develops the event after week j, and fij(Yi) is the posterior
probability of patient i developing the event after week j. Therefore, the BS is the
sum of squared prediction errors across all subjects who are still at risk at prediction
time k.
In the independent censoring scenario, we check the prediction accuracy of marginal
probabilities of patterns, together with the dynamic BS changing over prediction
times. First we evaluate the estimation of the marginal probability of each pattern.
The marginal probability of patterns has certain medical implications. First, it re-
flects the structure of the targeted population. Second, it represents the risk of events
71
when biomarker observations are not available. The squared error of marginal prob-
ability estimation is measured by the Euclidean distance between the true marginal
probability and the estimated one for each of the two methods. The lower the squared
error is, the better the estimation of marginal probabilities.
Figure 4.1: Squared error of marginal probability estimation of complete-case analysis
(red) and GPMM (green)
As shown in Figure 4.1, GPMM controls the squared error well, while complete-
case analysis loses efficiency in marginal probability estimation. This is because in
this independent censoring scenario, each pattern has a different probability of cen-
soring. The longer the true event time is, the more likely it is censored. Thus, the
relative frequency of patterns in the complete cases does not reflect the true distribu-
tion of patterns in the target population. GPMM, in contrast, redistributes censored
patients into different patterns. Therefore, it alleviates the effects of censoring in
estimating the marginal probability.
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Next, we examine the performance of prediction between the two models. Based
on the results shown in Figure 4.2, the Brier Scores of the two methods is similar.
GPMM achieves a higher BS in early predictions, but the effect size of this improve-
Figure 4.2: Differences of the dynamic Brier Score between GPMM and complete-case
analysis
ment is small. With more biomarkers available, the difference of BS between the two
methods decreases.
Table 4.1 lists the mean BS of GPMM, complete-case analysis, and the mean and
the standard deviation of the difference between the two methods. We found that the
complete-case analysis surpasses GPMM in later predictions when more biomarker
observations are available. This is because complete-case analysis, although it has
a reduced power due to the smaller sample size, provides unbiased estimation of
biomarker profiles over time. In contrast, GPMM incorporates censored cases into
each pattern with an adjusted weight, and results in a biased estimation of biomarker
profiles. When there are fewer than 8 biomarker observations, the effect of biased
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biomarker profile estimation is alleviated by more accurate marginal probabilities of
patterns; thus, GPMM does better in early predictions. However, when there are
Table 4.1: Brier Scores of GPMM and complete-case analysis in the independent cen-
soring scenario
Prediction at week 1 2 3 4 5 6 7 8 9 10
GPMM 0.146 0.247 0.375 0.484 0.587 0.675 0.729 0.773 0.828 0.873
Complete-case 0.140 0.241 0.369 0.479 0.584 0.674 0.732 0.780 0.835 0.882
Difference (mean) 0.006 0.006 0.005 0.005 0.002 0.001 -0.003 -0.007 -0.007 -0.009
Difference (SD) 0.005 0.008 0.013 0.019 0.031 0.039 0.042 0.055 0.061 0.064
more biomarker observations and fewer candidate patterns to predict, the effect of
unbiased biomarker profile estimation dominates the biased estimation of marginal
probabilities of patterns; thus, complete-case analysis does better in later predictions.
Therefore, there is a trade-off effect of biased biomarker estimation and more accurate
marginal probabilities of patterns.
In the dependent censoring scenario, the censoring time depends on the true event
time. We also check the prediction accuracy of marginal probabilities of patterns and
the dynamic BS changing over prediction time. As shown in Figure 4.3, GPMM con-
trols the squared error well, while complete-case analysis has an obvious larger error
in marginal probability estimation. This is because in the dependent censoring sce-
nario, times-to-censoring depend on true times-to-event, so that complete cases are
not a good representative of the target population. GPMM, however, estimates the
pattern of censored patients and thus adjusts the marginal probability of patterns.
Compared with the estimation error shown in Figure 4.1 when data are simulated
under independent censoring, the estimation errors of marginal probability for both
complete-case analysis and GPMM inflate.
Next, we check the performance of prediction between the two models. Based on
the results shown in Figure 4.4, GPMM, on average, obtains a higher BS than the
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Figure 4.3: Squared error of marginal probability estimation of complete-case analysis
(red) and GPMM (green)
complete-case analysis, no matter how many biomarker observations are available.
However, the increase in BS is close to 0.
Table 4.2 presents the mean BS of GPMM, complete-case analysis, the mean and
the standard deviation of the difference between the two methods. We found that
Table 4.2: Brier Scores of GPMM and complete-case analysis in the dependent cen-
soring scenario
Prediction at week 1 2 3 4 5 6 7 8 9 10
GPMM 0.146 0.237 0.334 0.416 0.473 0.520 0.557 0.600 0.656 0.749
Complete-case 0.140 0.232 0.330 0.414 0.471 0.519 0.556 0.598 0.655 0.748
Difference (mean) 0.006 0.005 0.004 0.003 0.002 0.001 0.001 0.003 0.001 0.001
Difference (SD) 0.005 0.007 0.009 0.015 0.019 0.023 0.027 0.030 0.032 0.029
GPMM does consistently better than landmark analysis, but the mean difference
of BS is relatively small compared to its standard deviation. In the independent
censoring scenario, we find that the unbiased estimation of biomarker profiles off-
sets the biased estimation of marginal probabilities. Thus, complete-case analysis
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Figure 4.4: Differences of the dynamic Brier Score between GPMM and complete-case
analysis
surpasses GPMM in later predictions. However, in the dependent censoring scenario,
the marginal probability estimation in complete case analysis does not reflect the true
distribution of patterns, and it produces more biased marginal probabilities than the
true ones, as demonstrated by Figure 4.3. Thus, the complete-case analysis is more
sensitive to censoring, especially dependent censoring. On the other hand, GPMM
better predicts the marginal probabilities of patterns.
4.4 Discussion
In this Chapter, we introduce how to apply the pattern mixture model to the
setting in which censored cases are allowed. In practice, censoring, or more generally
speaking, partially observed information, is very common. Complete-case analysis,
which ignores the censored cases, not only suffers from a lower power, but also results
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in a biased marginal probability estimation. GPMM, however, reweights the censored
cases and allows them to contribute to the model fitting given the information up to
the censoring time. As a result, GPMM has a more accurate estimation of marginal
probability. This benefit, as demonstrated in the simulation section, drives the im-
provement of GPMM over complete-cases analysis.
In this project, a sample of 220 patients are simulated as a training or test dataset.
We use 220 rather than 200 in Chapter III because we want to maintain enough
power for the complete-case analysis. With around 30% censoring, the complete-
case analysis uses dataset of 150 patients from eleven patterns. On the other hand,
GPMM has a much larger power due to its utilization of censored cases. Moreover, we
require enough cases within each pattern to achieve a robust estimation of the mean
pattern profile. However, in complete-case analysis with independent or dependent
censoring, it is likely that there are only a limited number of cases in some patterns.
Thus, if these cases are extreme cases, we might end up with biased estimations for
biomarker profiles. As demonstrated in Figure 4.1 and Figure 4.3, there are more
outliers of estimation in complete case than GPMM. Therefore, when there are only
limited number of patients, or if some of patterns have few patients, complete-case
analysis is not recommended.
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CHAPTER V
Bootstrap Methods for Determining the Number
of Latent Classes in Joint Modeling
5.1 Introduction
Joint modeling (JM) has been widely applied to medical studies in which both
the longitudinal biomarkers and the time-to-event are of interest. One type of JM,
joint modeling with latent classes (JMLC) has recently received extensive attention
and has been applied to the prediction of prostate cancer (Lin et al., 2002), AIDS
(Liu et al., 2015), severe hot flashes (Jiang et al., 2015) and dementia (Proust-Lima
et al., 2016). JMLC assumes the population consists of individuals in various latent
classes defined by the risk of the disease, and individuals from the same latent class
share the same distribution of the longitudinal biomarker and the time-to-event. One
prerequisite of applying JMLC is knowing the number of latent classes.
Although determining the number of latent classes in JMLC can be part of the
empirical data analysis when there is enough evidence in the data to show that mul-
tiple classes exist, prior knowledge regarding the exact number of classes is usually
unavailable. Generally speaking, we expect an adequate number of latent classes to
capture the heterogeneity of the biomarker patterns and the time-to-event distribu-
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tions in the population, while avoiding redundant components so that we can control
the overall complexity of JMLC.
Akaike information criterion (AIC) and Bayesian information criterion (BIC) are
current standard approaches used to choose the number of latent classes in JMLC
(Proust-Lima et al., 2014; Liu et al., 2015; Rouanet et al., 2016). These information-
based criteria are all measures of goodness of model fitting and add a penalty term for
complexity to the negative log-likelihood. The penalty term, 2k for AIC, and klog(n)
for BIC, is a function of the effective number of parameters k and the sample size n,
so that the final selected model achieves both a good fit to the data and parsimony
(Leroux, 1992; Keribin, 2000; Akogul and Erisoglu, 2016). The model with the small-
est value of AIC or BIC is preferred.
These information-based criteria quantify whether it is worth having a richer
model in terms of information gain. However, it is hard to quantify how much
practical information gain is associated with a one-unit change in BIC. Moreover,
AIC has been criticized for prefering models that contain more latent classes than
the actual number (Olofsen and Dahan, 2013). In general, the choice of the number
of latent classes should not only be based on the smallest information criterion, but
also on meaningful latent classes and a good discrimination between each latent class
(Proust-Lima et al., 2014). Therefore, this study considers other methods for choos-
ing the number of latent classes in JMLC.
JMLC is inspired by finite mixture modeling (Vermunt and Magidson, 2003;
Proust-Lima et al., 2014), so it is beneficial to review the methods for selection of
the number of latent classes in mixture models. Other than the information-based
criteria, another accepted method is regularization, which adds one or more penalty
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terms to the negative log-likelihood used for estimation. These penalty terms could
be functions of the probabilities of latent classes, or functions that summarize the
similarity between latent classes. The regularization method usually starts with an
adequately large number of latent classes, and then reduces the number by merging la-
tent classes with similar distributions of outcomes of interest together, and eliminates
latent classes with too few subjects (Chen and Khalili, 2008; Lindsten et al., 2011).
For example, consider a one-dimensional location mixture model with location pa-
rameters µ, where µ = (µ1, µ2, · · · , µJ) are the location parameters for latent classes
1, 2, · · · , J . A penalty function of difference of location parameters λ∑
i 6=j
f(µi − µj)
is added to the log-likelihood, where λ is the tuning parameter that larger λ results
in smaller number of latent classes. This penalty function forces similar location pa-
rameters to be equal, thus reducing the number of latent classes.
Another potential method for selection of the number of latent classes is through
hypothesis testing, such as the score test or likelihood ratio test (LRT) (Neyman and
Scott, 1965; Lindsay, 1995), which are extensively used in parametric model selec-
tion. Hypothesis testing starts with setting the null and alternative hypotheses for
the number of latent classes, and then calculates the null test statistic based on the
data. The p-value is calculated and used as the evidence to support or reject the
null hypothesis. Compared with AIC, BIC and regularization, the hypothesis testing
method is an inference process and quantifies the information in the data (p-value)
of choosing the number of latent classes.
The development and comparison of methods for selecting the number of latent
classes in mixture models is focused primarily on the mixtures of Gaussian distri-
butions (Lo et al., 2001; Akogul and Erisoglu, 2016). For example, Lo et al. (2001)
derived the asymptotic distribution of the LRT statistic testing the number of latent
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classes when the sample is drawn from a mixture of normal distributions. Akogul
and Erisoglu (2016) compared the performance of AIC and BIC to each other with
mixtures of multivariate normal distributions. The majority of practical analyses
use information-based criteria to select the number of latent classes in mixture mod-
els (Fonseca and Cardoso, 2007; Akogul and Erisoglu, 2016; Zhang, 2016; Mehrjou
et al., 2016), because the information-based criteria are comparatively easy to com-
pute. Tein et al. (2013) reviewed 38 published papers using latent profile analysis
and found that BIC is the most accepted criterion in model selection.
In this project, we propose a hypothesis testing method to select the number
of latent classes in JMLC. However, a LRT or score test should be applied with
caution in the latent class setting, as one of the regularity conditions for standard
asymptotics is violated. This condition requires that if the the log-likelihood function
is maximized at the true parameter ξ0, then ξ0 should be an interior point in its
support. Let us consider a test of H0 : J = 3 vs. H1 : J = 4, where J is the number
of latent classes. Two models are fitted assuming the outcome Y comes from the
corresponding distributions:
Y ∼
3∑
j=1
pijf(.|ξj)
Y ∼
4∑
j=1
pijf(.|ξj)
where pij is the marginal probability that Y is a member of latent class j, and ξj ∈ Ξp
is the p-vector of parameters in latent class j. Therefore the hypothesis of interest is
equivalent to H0 : pi4 = 0, ξ4 6= ξl vs. H1 : pi4 6= 0, ξ4 6= ξl, for l = 1, 2, 3. The null
value of pi4 lies on the boundary of its support [0, 1], so the asymptotic distribution
of the LRT statistic is not a χ2 distribution with p+ 1 degrees of freedom.
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Some research has developed the theoretical asymptotic null distribution of the
LRT statistic when the null hypothesis contains boundary values (Lo et al., 2001;
Crainiceanu and Ruppert, 2004; Stram and Lee, 1994). Lo et al. (2001) proved that
the LRT statistic, in a mixture of normal distributions testing k0 components against
the alternative normal mixture distribution with k1 components, has a null distribu-
tion that is a weighted sum of χ21 variables, which is not available in a closed form.
Similar conclusions are drawn from studies on likelihood ratio testing for zero variance
components in linear mixed models (Stram and Lee, 1994; Crainiceanu and Ruppert,
2004). Moreover, the joint distribution of the longitudinal biomarker observations
and time-to-event has a more complicated form than a mixture of normal distribu-
tions or longitudinal data. Though using LRT to select the number of latent classes
in JMLC seems plausible, this approach has been limited use due to the difficulty in
deriving the theoretic asymptotic null distribution of the LRT statistic.
As an alternative to deriving the theoretic null distribution of the LRT statistic, we
propose using the parametric bootstrap. Some research has discussed using the boot-
strap with the LRT for determination of the number of latent classes (McCutcheon,
1987; McLachlan, 1987; McLachlan and Peel, 2000). McLachlan (1987) described the
process of bootstrapping the LRT statistics in a mixture of normal distributions. A
more recent study by Karlis and Xekalaki (1999) introduced the use of parametric
bootstrap methods sequentially to identify the number of latent classes in a mixed
Poisson model. They claimed that when there are a sequence of candidate numbers of
latent classes, k, k+1, k+2, · · · , one should start the LRT with the lowest consecutive
pair k and k + 1. If the data offer enough evidence to reject the null hypothesis that
there are k latent classes, one will perform a LRT for the next consecutive pair k+ 1
and k + 2. The above process will be repeated until the first time one fails to reject
the null hypothesis. However, Karlis and Xekalaki (1999) did not adjust the type I
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error of these multiple tests since they used the same desired Type I error of 0.05 for
all the tests.
Research also exists on the power of the bootstrap LRT in mixture models (McLach-
lan and Peel, 2000; Nylund et al., 2007; Tekle et al., 2016). Nylund et al. (2007) shows
that the bootstrap likelihood ratio test is more consistent at identifying the correct
number of latent classes than the information-based criteria BIC. They generated
data under various scenarios, and they found that even at its worst, the bootstrap
likelihood ratio test successfully detects the true number of latent classes around 49%
of the time. However, in the same scenario with an eight-item categorical outcome,
BIC could not select the correct model. Moreover, the bootstrap likelihood ratio test
has the benefit of being consistently reliable regardless of sample size. However, after
reviewing 38 articles, Tein et al. (2013) found that the bootstrap LRT test is used less
for model selection in mixture models, compared with BIC, AIC, and other model
selection methods.
The bootstrap is primarily criticized for its computational burden. Nylund et al.
(2007) found that when applying the bootstrap LRT, the computation time increased
5 to 35 times in their examples, compared with using BIC to select the number of
latent classes. To mitigate the amount of computation time, Nylund et al. (2007)
set an early stopping rule for the bootstrap LRT, such that if the first nb bootstraps
demonstrated strong enough evidence to reject or fail to reject the null hypothesis,
one could stop drawing further bootstrap samples. However, this early stopping rule
is controversial, since it was specific to the scenario generated in Nylund et al. (2007).
Moreover, when the true p-value based on infinitely many replications is around 0.05,
the probability of agreement between their early stopping rule and the infinite repli-
cation procedure is less than 75%.
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We propose to select the number of latent classes in JMLC with the LRT, using
the parametric bootstrap to capture the null distribution of the LRT statistics. Our
research is motivated by the study of acute graft-versus-host disease (aGVHD) at
the University of Michigan. aGVHD is an inflammatory disease caused by a reaction
between the donors’ and recipients’ tissues among patients who have received bone
marrow transplantation. Patients’ times-to-aGVHD were recorded, together with
their biomarker observations up to the times-to-aGVHD or administrative censoring.
There are clearly at least two latent classes of patients: the first being patients who
will never develop aGVHD (aGVHD-free), and the second being patients who will ex-
perience aGVHD within 100 days of transplant. However, current research is unsure
of how many subgroups there are among the patients who will experience aGVHD
within 100 days.
In Section 5.2, we briefly introduce JMLC and describe how to select the number
of latent classes in JMLC with bootstrap LRT, together with early stopping methods
which adaptively reduce the number of bootstraps. Section 5.3 presents the simulation
results of bootstrap LRT with simulated aGVHD data. Concluding remarks and
discussion are given in Section 5.4.
5.2 Methods
In this section we describe how to apply JMLC to compute the MLEs of the longi-
tudinal process and the time-to-event process, and then specify using the parametric
bootstrap to select the number of latent classes in JMLC, followed by discussions on
adaptively reducing the number of bootstraps.
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5.2.1 JMLC model specification and model fitting
Let zi = (zi1, zi2, · · · , ziJ)′ represent the unobserved indicator vector of sub-
ject i’s latent class membership, where zih = 1 if subject i belongs to latent class
h = 1, 2, · · · , J , and 0 otherwise, and J is the number of latent classes. Let pii =
(pii1, pii2, · · · , piiJ)′ be the corresponding probabilities of latent class membership, and
pi = (pi1, pi2, · · · , piJ)′ be the marginal probabilities of subjects belonging to each
aGVHD class, with the restriction that
∑J
h=1 pih = 1.
For the longitudinal biomarker process, we define Y i = (Yi(t1), Yi(t2), · · · , Yi(tni))
as the biomarker history of subject i at times (t1, t2, · · · , tni), where ni is the to-
tal number of biomarker observations for subject i, for i = 1, 2, · · · , n. We specify
that patients from the same latent class share the same mean biomarker trajec-
tory, with individual-specific random effects bi reflecting the deviation of an indi-
vidual’s biomarker pattern from the mean of their latent class. The measurement
error ei = (ei(t1), ei(t2), · · · , ei(tni)) of biomarkers introduces the random noise in
biomarker measurement. We assume the joint of the observed biomarkers, Yi, ran-
dom effects, bi, and the measurement error, ei, Bi
′ = (Yi, bi, ei) given zih = 1 follows
a multivariate normal distribution, i.e.,
Bi|zih = 1 ∼MVN (

Xiβ
(h)
0
0
 ,

ZiDZ
T
i + σ
2Ini ZiD σ
2Ini
DZTi D 0
σ2Ini 0 σ
2Ini
) (5.1)
with density function fh(Bi), where Xi is the design matrix of function of time,
β(h) is the corresponding parameters of the mean biomarker trajectory in the la-
tent class h, Zi is the design matrix of random effects that can be any subset of
Xi, D is the covariance matrix of the random effects that is constant among all
different latent classes, and σ2 is the common variance of each element of ei. Let
85
ω = (β(1),β(2),β(3),β(4), D, σ2) denote all the parameters involved in the longitudi-
nal process.
For the time-to-event process, let Ti denote the observed event time for subject
i, which is the minimum of the time-to-event for subject i, T ∗i , and last follow-up
time Si. We also define δi as the indicator of whether subject i experiences the event
(δi = 1) or is censored (δi = 0). For simplicity, we assume the time-to-event follows
gh(Ti, δi|λh) distribution, for h = 1, 2, · · · , J , where λh are the parameters involved
in the time-to-event process in latent class h.
Let ξ = (pi,ω,λ) represent the complete parameter set; and
((Y1, T1, δ1), (Y2, T2, δ2), · · · , (Yn, Tn, δn))
are the n independent observed data containing both biomarker and time-to-event
observations. So the data likelihood function is:
L(ξ|B, T, δ) =
n∏
i=1
J∑
h=1
[pihfh(Bi|ω)gh(Ti, δi|λ)] (5.2)
with corresponding observed data log-likelihood:
l(ξ|B, T, δ) =
n∑
i=1
log{
J∑
h=1
[pihfh(Bi|ω)gh(Ti, δi|λ)]} (5.3)
The log-likelihood in Equation 5.3 based on observed data containing a summation
in the log function and as such it is inconvenient to maximize. We then introduce
the unobserved label of latent classes and construct the likelihood function based on
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the complete data (Bi, Ti, δi, zi). The complete data likelihood function is:
Lc(ξ|B, T, δ, z) =
J∏
h=1
[pihfh(Bi|ω)gh(Ti, δi|λ)]zih (5.4)
with corresponding log-likelihood:
lc(ξ|B, T, δ, z) = l1(pi|B, T, δ, z) + l2(ω|B, T, δ, z) + l3(ζ|B, T, δ, z) (5.5)
where l1(pi|B, T, δ, z) =
n∑
i=1
J∑
h=1
zihlog(pih), l2(ω|B, T, δ, z) =
n∑
i=1
J∑
h=1
zihlogfh(Bi|ω),
and l3(λ|B, T, δ, z) =
n∑
i=1
J∑
h=1
zihlog[gh(Ti, δi|λ)], which are three separable parts cor-
responding to pi, ω and λ. The Expectation-Maximization (EM) algorithm is used
to find the MLEs of parameters. Using the EM algorithm to maximize the aforemen-
tioned log-likelihood is not of key interest and the details are omitted here. Please
refer to Chapter II for further details.
5.2.2 Parametric bootstrap in JMLC
One prerequisite of using JMLC is specification of the number of latent classes
J . We postulate that the samples are from a mixture distribution with either J0 or
J1 components, where J0 and J1 are known integers with J0 < J1. By constructing
the corresponding log-likelihood functions as in Equation 5.5 under the null and al-
ternative hypotheses, H0 : J = J0 vs. H1 : J = J1 respectively, we compute the
MLEs ξˆ
J0
= arg maxΘJ0 l0(ξ
J0|Y, T, δ) and ξˆJ1 = arg maxΘJ1 l1(ξJ1|Y, T, δ) through
the EM algorithm as described in Section 5.2.1, where ΘJ0 is the parameter space
under the null hypothesis, which is nested within ΘJ1 , the parameter space under the
alternative hypothesis. Based on these MLEs, we calculate the observed LRT statistic
LRobs = 2(l1(ξˆJ1|Y, T, δ) − l0(ξˆJ0|Y, T, δ)) based on Equation 5.3. As discussed in
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the previous section, the exact asymptotic reference distribution of the LRT statistic
is difficult to derive. Thus we will use the parametric bootstrap to determine the
empirical distribution of the LRT statistic.
Specifically, we will simulate data (Y, T, δ)sim under the null hypothesis from
a mixture distribution of J0 components with parameters ξˆ
J0
in each bootstrap,
with a sample size equal to that in the original data. In the kth bootstrap, we fit
two individual models with J0 and J1 components, and obtain the corresponding
MLEs ξˆ
J0
sim and ξˆ
J0
sim, and the LRT statistic based on the simulated data LRksim =
2(l1(ξˆ
J1
sim|(Y, T, δ)sim)− l0(ξˆ
J0
sim|(Y, T, δ)sim).
We repeat the above process B times, and then compare the observed LRT statistic
LRobs to its empirical null distribution LRksim, for k = 1, 2, · · · , B. For a given α
level, we will reject the null hypothesis when
B∑
k=1
I(LRobs > LRksim)/B > 1 − α. In
other words, the p-value for this bootstrap LRT is:
p =
B∑
k=1
I(LRobs ≤ LRksim)/B (5.6)
In order to capture the tail of this empirical null distribution, we need to choose an
adequately large value for B. In practice, B is usually defined at 1, 000, 2, 000, or
10, 000 (Efron and Tibshirani, 1993; MacKinnon, 2009; Hesterberg, 2015).
It is well-known that the results of the EM algorithm depend on the initial param-
eter values (Karlis and Xekalaki, 2003; Biernacki et al., 2003). Therefore, to eliminate
the effect of initial values, we suggest that after choosing the ideal initial parameter
values for both JMLC with J0 and J1 components in the observed data, we save the
two starting values and use them repeatedly in the bootstrap samples.
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5.2.3 Adaptively reducing the number of bootstraps
In the previous section, we stated that we needed to choose a sufficiently large
number of bootstrap samples to detect the behavior of LRT at the tail of its empirical
distribution. We chose to use B = 1, 000 in our methods. Obviously, if we could use
fewer bootstraps but draw the same conclusion as with 1,000 bootstraps, we could
save computational time. Moreover, we need to control the overall Type I error with
fewer bootstraps to remain at the desired α−level, as well as maintain the power of
the LRT.
To obtain reliable results based on a smaller value of B, Davidson and MacKin-
non (2000) introduced an iterative procedure. They proposed to start with a small
B0, and then evaluate whether the p-value obtained with these B0 bootstraps is evi-
dence to reject the null hypothesis. If the p-value based on these B0 bootstraps was
Pˆ r(B0) < α, then one would further test H0 : Pr(B0) < α vs. H1 : Pr(B0) ≥ α,
at a pre-specified significance level β, which was chosen to be small, say 0.001. This
test was done through a binomial approximation for the number of bootstrap samples
that had statistics larger than our observed value. This significance level β could be
viewed as a tuning parameter, which controlled how much we could believe in the
results based on these B0 bootstraps, and controlled the total number of bootstraps
needed. This process was continued with increasing B0 until the first time we failed
to reject the null hypothesis or until we reached the upper bound of the number of
bootstraps.
In another study, Nylund et al. (2007) discussed a sequential early stopping rule
for bootstrap LRTs. The basic idea was to choose an adaptive α-level for each number
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of bootstraps. If the p-value calculated based on the first 49 bootstraps was exactly
zero, Nylund et al. (2007) suggested stopping and rejecting the null hypothesis. If
the p-value based on the first 49 bootstraps was greater than zero, one continued the
bootstrap process and rejected the null hypothesis with 78 bootstraps if the p-value
based on these 78 bootstraps was no more than 1/78. Together with this rule, Nylund
et al. also introduced an early stopping rule when the data showed strong evidence
that we would fail to reject the null. More specifically, if the p-values based on the
first two or three bootstraps were ≥ 1 and ≥ 2/3, respectively, one would stop and
conclude that we had failed to reject the null hypothesis. This sequential rule was
justified by the concordance of its conclusion with the conclusion drawn with infinite
bootstraps. The concordance probability showed that when the p-value based on an
infinite number of bootstraps was quite different from the targeted α− level, this
early stopping rule supported above 95% concordance with the infinite bootstraps.
However, when the p-value based on infinite bootstraps was around the targeted α-
level, the concordance probability was only around 65%.
The early stopping method introduced by Davidson and MacKinnon (2000) is a
testing process that requires one to evaluate the results at each candidate value of
B0. In contrast, the method proposed by Nylund et al. (2007) is a rule that is de-
signed before running bootstraps. Moreover, in the iterative method by Davidson and
MacKinnon (2000), the significance level β at each candidate number of bootstraps
should be chosen with caution. With an overly small significance level, the early stop-
ping rule is irrelevant because there is very little chance to reject the null hypothesis
that H0 : Pr(B0) < α0. In contrast, an overly large significance level might lead to
early stopping with the wrong conclusion. However, in Nylund et al.’s method, early
stopping based on only two or three bootstraps is questionable. The concordance
probability that Nylund et al. used to justify their early stopping rule only reflects
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the percentage of making wrong conclusions, but it does not distinguish the chance
to make a false positive or negative conclusion. Thus, we propose a new sequential
early stopping rule that maintains a desired Type I error rate; we will examine the
power of our approach via simulation.
We consider two types of early stopping. The first is stopping early in favor of
not rejecting the null hypothesis. For example, if we run B = 1000 bootstraps at
α = 0.05 and observe more than 50 bootstrap LRT statistics larger than the observed
LRT statistic based on original data, we would fail to reject the null hypothesis. In
that case, if we observe more than 50 bootstraps with larger LRT statistics within
the first Bm (Bm ≤ B) bootstraps, we can stop after Bm bootstraps, and conclude
that we have failed to reject the null hypothesis. This type of early stopping will not
affect the Type I error or power of the bootstrap LRT, compared with B bootstraps.
The other type of early stopping is in favor of rejecting the null hypothesis. Simi-
lar to Nylund et al., we set a sequential stopping rule that at the pre-chosen numbers
of bootstrap samples B1, B2, · · · , we assess the numbers of bootstraps with larger
LRT statistics, and compare them to pre-specified upper thresholds U1, U2, · · · . More
specifically, if we observe F1 out of B1 bootstraps with larger LRT statistics, with
F1 =
∑B1
k=1 I(LRT
k
sim ≤ LRTobs) ≤ U1, we will stop and conclude that we have re-
jected the null hypothesis. If we fail to reject the null hypothesis with the first B1
bootstraps, we will continue with more bootstraps. At the mth decision point, which
occurs with Bm bootstraps, we will calculate the number of bootstraps with larger
LRT statistics than the original one and compare this number Fm with the threshold
Um. As long as the number of larger LRT statistics is between Um and αB, we will
continue the bootstrap process until we complete B bootstraps, and draw the final
conclusion given the complete B bootstraps.
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The sequence of the early stopping rule values ((B1, U1), (B2, U2), · · · ) is analogous
to an alpha-spending function in clinical trials (Demets and Lan, 1994). The thresh-
olds Um should be chosen to control the overall Type I error and also minimize the
loss of power. For example, if we set the targeted α-level at 0.05 for 1000 bootstraps,
and we observe 2 bootstrap LRT statistics larger than the observed LRT statistic of
the original data within the first 200 bootstraps, it is reasonable for us to believe that
we will end up rejecting the null hypothesis with 1000 bootstraps. However, we could
also make an incorrect decision. If we observe more than 48 larger bootstrap LRT
statistics within the next 800 bootstraps, we might falsely reject the null hypothesis
with the first 200 bootstraps.
With a targeted overall α-level at 0.05 and an upper bound of B at 1000, we
propose two rules ((B1, U1), (B2, U2), · · · ) for comparison:
• Rule 1: (200, 8), (400, 17), (600, 22), (800, 30), (1000, 40)
• Rule 2: (200, 6), (400, 14), (600, 26), (800, 35), (1000, 47)
These two rules make decisions in increments of 200 bootstraps, so that at most five
assessments are made. Both of these rules control the overall Type I error to be no
more than 0.05. The calculation details of Type I error can be found in Appendix A.1.
Unlike the Type I error, evaluating the above two candidate rules with regards
to power is not straightforward. This is because the distribution of p-values under
the alternative hypothesis is a function of both sample size and the effect size in the
alternative hypothesis, making it difficult to derive in closed form. Given that the p-
value under the null hypothesis follows a uniform distribution, which is a special case
of a Beta distribution, we hypothesize a theoretical Beta (1,31.4) distribution for the
p-value under the alternative hypothesis. If a variable X follows a Beta (1,31.4) distri-
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bution, the probability of X less than 0.05 is around 0.8. In other words, if the p-value
for one test under the alternative hypothesis follows a Beta (1,31.4) distribution, then
the power of this test is around 0.8. When applying our two candidate rules, the losses
of power for these rules are 0.0136 and 0.0069, respectively. It is because in order to
reject the null hypothesis, both of the two rules require a more restricted p-value than
0.05. It is clear that the loss of power is controlled by the largest value of Um, so that
candidate rule 1 has the larger loss of power. However, compared with the targeted
power 0.8, both of these losses of power are relatively trivial. Moreover, the choice
of rules should also take the computational time into consideration. Rule 1 is more
likely to terminate the bootstrap process earlier because it is more tolerant in early
stages. We will evaluate the power of the two stopping rules in the simulation section.
In practice, we will apply the early stopping rules in favor of both the null and the
alternative hypothesis simultaneously. As demonstrated in Figure 5.1, the number
of bootstraps with larger LRT statistics than that observed is calculated at every
200 bootstraps. If that number falls in the “rejecting zone”, one will stop there and
reject the null hypothesis. On the other hand, the early stopping in favoring of the
null hypothesis is assessed whenever a new bootstrap is available after the first 50
bootstraps. As soon as the number of bootstraps with larger LRT statistics falls into
the “fail to reject zone”, one will stop and fail to reject the null hypothesis. Otherwise,
if that number falls between the two threshold lines, one will draw an additional 200
bootstraps and apply the next decision rule.
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Figure 5.1: Diagram of early stopping rules adaptively reducing the number of boot-
straps (left: rule 1; right: rule 2)
5.3 Simulation and Result
5.3.1 Comparing Bootstrap LRT and BIC
The purpose of this simulation is to examine the Type I error and the power of
bootstrap LRT in testing one pair of candidate numbers of latent classes. The BICs
of the two models with different numbers of latent classes are also calculated. The
accuracy rate of model selection based on BIC, which is defined as the proportion of
times that the true model has a lower BIC, is calculated. We use BIC as a benchmark,
and evaluate the performance of bootstrap LRT relative to BIC.
Here we focus on testing one pair of candidate numbers of latent classes: H0 : J0 =
3 vs. H0 : J1 = 4. Data are simulated under both the null and alternative hypotheses
in order to examine the Type I error and the power of the parametric bootstrap LRT,
respectively. One thousand simulations are run under each hypothesis.
In each simulation, a sample of 180 patients is generated. Given the latent class,
each patient’s biomarker observations are generated from a linear mixed model, with a
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class-specified mean biomarker trajectory and a common variance-covariance matrix
for random effects shared across latent classes. The times-to-aGVHD follow Weibull
distributions with class-specified shape and scale parameters, except for the aGVHD-
free patients. Biomarker values of each patient are collected weekly right after the
transplant, until the earliest of onset of aGVHD or day 100. Since we assume that
the baseline biomarker value is non-informative for time-to-aGVHD, we require that
each subject should have at least two observations. As patients who develop aGVHD
within one week after the transplantation will be removed from the study, the sample
size might be slightly less than 180. The patients’ times-to-aGVHD are recorded
together with the biomarker values. Two JMLC models are fitted under the null hy-
pothesis J0 = 3 and the alternative J1 = 4, respectively. The observed LRT statistic
LRTobs is calculated and recorded. One thousand parametric bootstrap samples are
generated from the null distribution (J0 = 3) as described in Section 5.2.2. We set
the desired Type I error rate at α = 0.05, and reject the null hypothesis in each
simulation if
1000∑
k=1
I(LRT obs > LRT ksimu)/1000 > 1− α.
First we simulate data under the null hypothesis H0 : J0 = 3, and test against the
alternative hypothesis of H1 : J1 = 4. Figure 5.2 presents a sample of data we simu-
lated; the left panel shows the observed biomarker values overall, while the right panel
highlights the values by latent group membership. With the 1,000 simulations under
this scenario, we calculate the probability of rejecting the null hypothesis, which is
the Type I error of the parametric bootstrap LRT. We also calculate the proportion
of times that the joint model with three latent classes has a lower BIC than the joint
model with four latent classes.
In these 1,000 simulations, 54 simulations reject the null hypothesis according to
the bootstrap LRT, so the Type I error of bootstrap LRT is 0.054. However, 710 sim-
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Figure 5.2: Biomarker observations of patients from three latent classes (left: overall;
right: by latent groups)
ulations show that joint model with four latent classes is preferred in terms of lower
BIC; the accuracy rate for BIC is therefore 29%. The bootstrap LRT controls the
Type I error well, while BIC shows a low accuracy rate when the data are simulated
from the null distribution.
In order to evaluate the power of the parametric bootstrap LRT, data are sim-
ulated under the alternative hypothesis H1 : J1 = 4. Figure 5.3 presents a sample
biomarker data of patients from four latent groups. Though the four latent classes are
highlighted in the right panel, it is hard to tell whether there are three or more latent
classes. With the 1,000 simulations under this setting, we calculate the probability
of rejecting the null hypothesis, which is the power of the parametric bootstrap LRT.
We also calculate the proportion of times that the joint model with four latent classes
has a lower BIC than the joint model with three latent classes.
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Figure 5.3: Biomarker observations of patients from four latent classes (left: overall;
right: by latent groups)
Out of those 1,000 simulations, 727 simulations reject the null hypothesis accord-
ing to the bootstrap LRT, so the power of bootstrap LRT is 0.727. Out of these 1000
simulations, 992 simulations show that the joint model with four latent classes are
preferred in terms of lower BIC. The accuracy rate for BIC is 99.2%.
Compared the results listed above, we found that BIC tends to favor more com-
plex models while bootstrap LRT achieves good power while controls the Type I error.
5.3.2 Type I Error and Power of Bootstrap LRT with Adaptive Reduction
in the Number of Bootstraps
In this section we will apply the two candidate early stopping rules introduced in
Section 5.2.3, together with the early stopping rule in favor of the null hypothesis, to
the simulation settings examined in Section 5.3.1. We will first evaluate the Type I
error of the two rules, followed by the power and the computational time of the two
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rules.
Recall that the early stopping rule in favor of the null hypothesis states that we
will stop generating bootstrap samples within the first Bx (Bx ≤ B) bootstraps if
more than 50 of the Bx samples have larger LRT statistics than the observed LRT
statistic, we will conclude that we have failed to reject the null hypothesis. Among
our 1000 simulations, the average number of bootstraps was 212. This means with
this early stopping rule in favor of the null hypothesis, we reduced our computational
times by 80% when the null hypothesis is true.
When applying rule 1, 51 out of 1000 simulations reject the null hypothesis, so the
Type I error for rule 1 is 0.051; when applying rule 2, 53 out of 1000 simulations reject
the null hypothesis, so the Type I error for rule 2 is 0.053. The two rules are more
conservative requiring no more than 40 or 47 bootstraps with larger LRT statistics,
compared with standard rule that requires no more than 50 bootstraps out of 1000.
When applying rule 1, the average number of bootstraps is reduced to 173; and the
average number of bootstraps is 178 when applying rule 2.
Given the data are simulated under the alternative hypothesis, the average num-
ber of bootstraps among these 1000 simulations is 839 when apply the early stopping
rule in favor of the null hypothesis. This means with this early stopping rule, we
reduce our computational time by approximately 16%.
When applying rule 1, 730 out of 1000 simulations reject the null hypothesis, so
the power for rule 1 is 0.730; when applying rule 2, 728 out of 1000 simulations reject
the null hypothesis, so the power for rule 2 is 0.728. The difference between these
values is due to 23 simulations, summarized in Table 5.1.
For example, based on results of all 1,000 bootstraps in simulations 2, 9, and 10,
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Table 5.1: 23 simulation results with contradictory conclusions based on early stop-
ping rules and 1000 bootstraps
ID
Number of larger LRT statistics within first N* bootstraps
Rule 1 Rule 2
1000
200 400 600 800 1000 Bootstraps
1 7 18 27 40 51 1 0 0
2 6 17 32 45 51 1 1 0
3 10 18 23 33 44 0 1 1
4 3 13 31 38 51 1 1 0
5 10 19 28 42 48 0 0 1
6 10 20 30 38 41 0 1 1
7 11 19 29 36 43 0 1 1
8 7 16 28 42 51 1 0 0
9 4 15 27 34 51 1 1 0
10 6 25 35 45 51 1 1 0
11 12 23 31 36 48 0 0 1
12 8 24 38 47 51 1 0 0
13 12 25 29 37 48 0 0 1
14 8 30 45 51 51 1 0 0
15 8 28 46 51 51 1 0 0
16 13 22 31 39 48 0 0 1
17 7 20 34 46 51 1 0 0
18 12 21 27 36 44 0 1 1
19 7 19 30 43 51 1 0 0
20 9 15 25 46 51 1 1 0
21 7 17 34 44 51 1 0 0
22 10 22 31 40 43 0 1 1
23 13 19 27 37 45 0 1 1
one would have failed to reject the null hypothesis. However, when applying the two
early stopping rules, one would stop early and reject the null hypothesis. In contrast,
the 1,000 bootstraps in simulations 5 and 11 support the alternative hypothesis, while
with these two early stopping rules, one would fail to reject the null hypothesis.
When applying rule 1, the average number of bootstraps is reduced to 264, while
the average number of bootstraps is 280 when applying rule 2. Both of the two rules
obviously reduce computational times, but are able to maintain sufficient power.
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5.4 Discussion
In this project, we described the procedure of the bootstrap LRT in the selection
of the number of latent classes in JMLC, and explore the performance of bootstrap
LRT in terms of Type I error and testing power. BIC, the current standard of model
selection in the number of latent classes, tends to select a more complex model with
more latent classes. Compared with BIC, bootstrap LRT controls well the Type I
error, and maintain sufficient power.
BIC adds a penalty term for the number of parameters in the model, k, to the
negative log-likelihood. Thus, the difference of BICs between two nested models
equals the LRT statistic, minus a value c which only depends on the difference of
the numbers of parameters in the two models and the sample size n, as shown in
Equation 5.7:
BIC(M0)−BIC(M1) = 2[log(lM1)− log(lM0)]− log(n)[kM1 − kM0 ] (5.7)
Bootstrap method find an empirical threshold, l∗, for LRT statistics that if the ob-
served LRT statistic is above l∗, one will reject the null hypothesis. According to
Equation 5.7, the bootstrap process is equivalent to selecting the richer model M1
if the difference of BICs between the two model M0 and M1 is larger than l
∗ + c.
Thus, one model is selected if the difference of BICs between two models exceeds a
threshold. However, in practice, we do not know this threshold.
In order to make a robust selection of the number of latent classes, one needs to
choose a sufficiently large B, which leads to the computational burden of bootstrap
LRT. In our project, we propose two candidate early stopping rules in favor of the
alternative hypothesis that can adaptively reduce the number of bootstraps. These
100
two rules examine the results of every 200 bootstraps, and will terminate the boot-
strap process if there is already enough evidence to reject the null hypothesis given
available bootstraps. The simulation results suggest that these two rules will not
cause dramatic power loss, but save the computation times significantly.
In contrast to the early stopping rule in favor of the null hypothesis, which as-
sesses the bootstraps results whenever a new bootstrap is generated, these two rules
only examine the bootstrap results when every additional 200 bootstraps are avail-
able. This is because the early stopping rule in favor of the null hypothesis does
not change the Type I error or power. The two early stopping rules in favor of the
alternative hypothesis, however, might change the Type I error and the power of the
bootstrap process. Without careful correction of the Type I error at each assessment,
multiple testing will inflate the overall Type I error. The upper bounds used with
1,000 bootstraps in our two rules are set to be 40 and 47, respectively, to control
for the overall Type I error. One could always change these rules, for example, by
assessing the bootstrap results whenever an additional 100 bootstraps are available.
In an extreme example, Nylund et al. (2007) drew conclusions using only the first
two or three bootstraps. In our project, we propose to assess the bootstrap results
with every 200 bootstraps to balance the computational time and the reliability of
the results. Conclusions drawn with too few bootstraps are questionable due to ran-
domness, while too many bootstraps will harm our goal of saving computational time.
The two early stopping rules we proposed in Section 5.2.3 are two examples that
reach a good balance between adequate power and manageable computation time.
More specifically, we do not lose too much power due to multiple assessments, but
can save considerable computation time. With a targeted overall Type I error and a
fixed maximum number of bootstraps B, one could construct his/her own early stop-
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ping rules in favor of the alternative hypothesis. One could update his/her decision
when every additional Bm bootstraps are available, and evaluate the results with a
customized upper limit list (U1, U2, · · · ).
In practice, we might not have one specific pair of numbers of latent classes, J0
and J1, to test, but rather an ordered sequence of candidate values J0, J1, · · · , Jmax,
where Jmax is the maximum possible number of latent classes. Schlattmann and
Bo¨hning (1993) described a backward selection process, where they failed to reject
the first hypothesis H0 : J = 4 vs. H1 : J = 5 but rejected the second one H0 : J = 3
vs. H1 : J = 4, both at an α-level at 0.05. Karlis and Xekalaki (1999), in contrast,
proposed a forward selection process. Here we describe how to select the number of
latent classes through a sequential testing process, while correcting for overall Type
I error.
If there is no prior information on the number of latent classes, we usually start
with the assumption of homogeneous samples (J0 = 1), testing this hypothesis against
a mixture distribution of two components (J1 = 2). If there is enough evidence to
reject the null hypothesis, we would move on to test two components against three,
then three against four, and so forth. We would stop the first time we fail to re-
ject H0 : J0 and conclude that there are J0 latent classes in the population. In our
aGVHD setting, patients are from at least two latent classes, the aGVHD-free class
and aGVHD class, so we would start with H0 : J0 = 2.
In this sequential testing process, we need to control the overall Type I error.
Many sequential testing methods have been proposed and widely applied. For ex-
ample, the study by Schlattmann and Bo¨hning (1993) discussed the limitations of
Bonferroni adjustment, which are the dramatic loss of power and inconsistent esti-
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mation of proportions of subgroups. Another method, the alpha-spending function
proposed by Demets and Lan (1994), which is widely used in interim analysis in clin-
ical trials.Similar work has been done in detecting the change point in proportional
hazard models (Goodman et al., 2011; He et al., 2013), and we adopt their alpha-
spending function.
Goodman et al. (2011) gave a brief proof of why their method can control the
overall Type I error . A more detailed proof of Type I error control in aGVHD set-
ting can be found in the Appendix A.2.
If the overall significance level is α, we will use an alpha-spending function α∗(m) =
α/2m−2, where α∗(m) is the significance level for hypothesis test: H0 : J = m vs.
H1 : J = m + 1. Thus, if we start with testing H0 : J = 2 vs. H1 : J = 3, we
will use the significance level of 0.05; if we reject the null hypothesis and move on to
test H0 : J = 3 vs. H1 : J = 4, we will use the new significance level of 0.025, and
so forth. In other words, each hypothesis will be tested under a more conservative
significance level than the previous hypothesis.
It is worth noting that one major advantage of this alpha-spending function is
that its calculation does not require setting the upper bound of the number of latent
classes. As long as the data present enough evidence to reject the null hypothesis,
one could continue testing the next consecutive pair of the numbers of latent classes.
103
CHAPTER VI
Summary
In this dissertation, we build three prediction tools to dynamically predict the
onset of aGVHD with longitudinal biomarkers. Our approaches have the ability to
identify subgroups of various risk, and refine the aGVHD prediction whenever a new
biomarker observation is available.
We have contributed to the existing literature on the application and model se-
lection of JMLC. Our bootstrap method in selecting the number of latent classes has
been proved to be more robust than the standard information-based criteria. It has
been demonstrated that our method controls the Type I error well while maintaining
sufficient power. We have also proposed two sequential early stopping rules, which
can save around 80% of the computational time.
We have proposed a revised landmark analysis, which uses all the information up
to the landmark time to identify the subgroups of aGVHD risk. In contrast to the
standard landmark analysis which uses only the biomarker observation at the land-
mark time, our approach can alleviate the effect of the measure error and provide
more efficient aGVHD prediction.
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We have also explored the performance of the pattern mixture model in our set-
tings. The pattern mixture model is easy to execute and straightforward to interpret.
Simulations have indicated that the pattern mixture model controls loss of accuracy
in predictions. Moreover, we have generalized the pattern mixture model by incorpo-
rating censored cases. The simulation results have demonstrated that this generalized
pattern mixture model results in more accurate estimations of the marginal pattern
probability, and thus achieves higher prediction accuracy compared to the complete-
case analysis of early predictions.
We have discussed the future work for each project in the corresponding discussion
section for each chapter. Furthermore, we are also planning to develop a user-friendly
application to allow better bench-to-bedside translational statistical tools.
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APPENDIX A
Bootstrap Likelihood Ratio Test: Type I Error
A.1 Type I error of the adaptive early stopping rule
When the null hypothesis is true, the p-value of the LRT test follows a uniform
distribution in [0, 1], which is equivalent to a Beta distribution B(1, 1). Under the null
hypothesis, the probability of observing no more than N1 bootstrap LRT statistics
larger than the observed one among the first 200 bootstraps is:
Pr
(
200∑
k=1
I(LRobs ≤ LRksim) ≤ N1|H0
)
=
1∫
0
N1∑
l=0
(
200
l
)
pl(1− p)200−ldp
=
N1∑
l=0
200!
l!(200− l)!
Γ(l + 1)Γ(201− l)
Γ(202)
=
N1∑
l=0
1/201
=
N1 + 1
201
Under the null hypothesis, the probability of observing more than N1 larger boot-
strap LRT statistics with the first 200 bootstraps, but no more than N2 within the
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first 400 bootstraps is:
Pr
(
200∑
k=1
I(LRobs ≤ LRksim) > N1,
400∑
k=1
I(LRobs ≤ LRksim) ≤ N2|H0
)
=
1∫
0
N2∑
l=N1+1
(
200
l
)
pl(1− p)200−l[
N2−l∑
m=0
(
200
m
)
pm(1− p)200−m]dp
=
N2∑
l=N1+1
N2−l∑
m=0
(
200
l
)(
200
m
) 1∫
0
pl+m(1− p)400−l−mdp
=
N2∑
l=N1+1
N2−l∑
m=0
200!300!
501!
(l +m)!(400− l −m)!
l!m!(200− l)!(200−m)!
Similarly, we can derive the formula to calculate the probability of observing more
than (N1, N2, · · · , Nq) larger bootstrap LRT statistics with the first (B1, B2, · · · , Bq)
bootstraps, respectively, but no more than Nq+1 within the first Bq+1 bootstraps.
With appropriate choice of (N1, N2, · · · ) together with (B1, B2, · · · ), one can design
the early stopping rule that controls the overall Type I error.
For example, with the early stopping rule 1 introduced in Section 5.2.3, that one
will stop the bootstrap LRT process and conclude that one has rejected the null
hypothesis if there are no more than eight bootstraps within the first 200 bootstraps
having larger LRT statistics than the observed one. If one fails to reject the null
hypothesis, he will continue and revisit the bootstraps LRT statistics at the 400th
bootstrap. Here we will calculate the Type I error of the early stopping rule 1: (200,8),
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(400, 17), (600, 22), (800, 30), (1000, 40).
Pr
(
200∑
k=1
I(LRobs ≤ LRksim) ≤ 8|H0
)
= 0.044776
Pr
(
200∑
k=1
I(LRobs ≤ LRksim) > 8,
400∑
k=1
I(LRobs ≤ LRksim) ≤ 17|H0
)
= 0.004114
Pr
(
200∑
k=1
I(LRobs ≤ LRksim) > 8, · · · ,
600∑
k=1
I(LRobs ≤ LRksim) ≤ 22|H0
)
= 0.000163
Pr
(
200∑
k=1
I(LRobs ≤ LRksim) > 8, · · · ,
800∑
k=1
I(LRobs ≤ LRksim) ≤ 30|H0
)
= 0.000314
Pr
(
200∑
k=1
I(LRobs ≤ LRksim) > 8, · · · ,
1000∑
k=1
I(LRobs ≤ LRksim) ≤ 40|H0
)
= 0.000601
Given these calculation results, the probability of rejecting the null hypothesis when
the null hypothesis is true, is 0.049968, which is controlled under 0.05.
A.2 Overall Type I error control proof
Right now we will prove that the aforementioned sequential significance levels
α∗(m) for m = 1, 2, · · · achieve an overall type 1 error no larger than α. Starting
with no further information of the aGVHD patients, in other words, J = 2, the
probability of reject null hypothesis H0 : J = 2 is:
Pr(Jˆ > 2|J = 2) = Pr(Jˆ = 3, 4, · · · |J = 2)
= Pr(Jˆ = 3|J = 2) + Pr(Jˆ = 4|J = 2) + Pr(Jˆ = 5|J = 2) + · · ·
= α(1− α
2
) + α
α
2
(1− α
4
) + α
α
2
α
4
(1− α
8
) + · · ·
= α−
∞∏
m=1
α
2m−1
≤ α
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Similarly, if the null hypothesis J = m is true, then the probability of reject null hy-
pothesis is definitely smaller than α. So the overall Type I error in the aforementioned
sequential testing process is bounded by α.
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